document incorporate reference portion abbvie inc proxy statement incorporate reference iii definitive proxy statement file march abbvie inc year end december table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure information executive officer ii item market registrant common equity relate stockholder matter issuer purchase equity security item reserve item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information item c disclosure foreign jurisdiction prevent inspection iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accounting fee service iv item exhibit financial statement schedule item summary signature item business overview abbvie company refer abbvie inc abbvie inc consolidate subsidiary context require abbvie global diversify researchbase biopharmaceutical company position success comprehensive product portfolio leadership position immunology oncology aesthetic neuroscience eye care abbvie use expertise dedicated people unique approach innovation develop market advanced therapy address world complex disease abbvie incorporate delaware april january abbvie independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott shareholder segment abbvie operate single global business segment dedicate research development manufacturing commercialization sale innovative medicine therapy operating structure enable chief executive officer chief operating decision maker codm allocate resource assess business performance global basis order achieve establish longterm strategic goal consistent structure global research development supply chain organization responsible discovery development manufacturing supply product commercial effort coordinate marketing sale distribution product organize geographic region therapeutic area activity support global corporate administrative staff determination single business segment consistent consolidated financial information regularly review codm purpose assess performance allocate resource planning forecasting future period note segment geographic area information consolidated financial statement include item financial statement supplementary data sale information relate abbvie key product geography include item management discussion analysis financial condition result operation product abbvie portfolio product include broad line therapy address world complex disease immunology product abbvie maintain extensive immunology portfolio rheumatology dermatology gastroenterology abbvie immunology product address unmet need patient autoimmune disease product humira humira adalimumab biologic therapy administer subcutaneous injection approve treat follow autoimmune disease united states canada mexico collectively north america european union condition principal market rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylose spondylitis north america european union adult crohn disease moderate severe north america european union plaque psoriasis moderate severe chronic north america european union juvenile idiopathic arthritis moderate severe polyarticular north america european union ulcerative colitis moderate severe north america european union axial spondyloarthropathy european union pediatric crohn disease moderate severe north america european union hidradenitis suppurativa moderate severe north america european union pediatric enthesitisrelate arthritis european union noninfectious intermediate posterior panuveitis north america european union pediatric ulcerative colitis moderate severe canada european union pediatric uveitis north america european union form khumira approve japan treatment intestinal behet disease pyoderma gangrenosum humira sell numerous market worldwide include japan china brazil australia account approximately abbvie total net revenue skyrizi skyrizi risankizumab interleukin il inhibitor selectively block il bind p subunit biologic therapy approve treat follow autoimmune disease north america european union japan condition principal market plaque psoriasis moderate severe north america european union japan psoriatic arthritis european union adult crohn disease moderate severe canada european union skyrizi approve japan treatment plaque psoriasis psoriatic arthritis erythrodermic psoriasis patient inadequate response conventional therapy induction maintenance moderately severely active crohn disease skyrizi approve multiple country globally include united states canada european union treatment moderate severe plaque psoriasis adult candidate systemic therapy phototherapy psoriatic disease psoriasis psoriatic arthritis skyrizi administer quarterly subcutaneous injection follow induction dose administer crohns disease skyrizi give induction dose iv infusion follow subcutaneous injection onbody injector week rinvoq rinvoq upadacitinib oral oncedaily selective reversible jak inhibitor approve treat follow inflammatory disease north america european union japan condition principal market rheumatoid arthritis moderate severe north america european union japan psoriatic arthritis canada european union japan ankylose spondylitis european union atopic dermatitis moderate severe canada european union japan axial spondyloarthropathy european union ulcerative colitis european union united states rinvoq indicate treatment moderate severe active rheumatoid arthritis active psoriatic arthritis moderately severely active ulcerative colitis active ankylose spondylitis active nonradiographic axial spondyloarthritis adult patient inadequate response intolerance tnf blocker indicate treatment moderate severe atopic dermatitis adult child year age old disease adequately control systemic drug product include biologic use therapy inadvisable european union rinvoq indicate treatment moderate severe rheumatoid arthritis adult active psoriatic arthritis adult inadequate response intolerance diseasemodifye antirheumatic medicine dmard active axial spondyloarthritis adult indicate treatment moderate severe atopic dermatitis adult child year age old moderately severely active ulcerative colitis adult oncology product abbvie oncology product target complex difficulttotreat cancer product imbruvica imbruvica ibrutinib oral oncedaily therapy inhibit protein call bruton tyrosine kinase imbruvica medicine receive united states food drug administration fda approval grant breakthrough therapy designation therapy receive separate designation imbruvica currently approve treatment adult patient blood cancer chronic lymphocytic leukemia cll certain form nonhodgkin lymphoma imbruvica approve adult pediatric patient year old chronic graft versus host disease failure line systemic therapy venclextavenclyxto venclexta venetoclax bcell lymphoma bcl inhibitor treat hematological malignancy venclexta approve fda adult cll small lymphocytic lymphoma addition venclexta approve combination azacitidine decitabine lowdose cytarabine treat adult newlydiagnose acute myeloid leukemia year age old medical condition prevent use standard chemotherapy aesthetic product abbvie aesthetic portfolio consist facial injectable plastic regenerative medicine body contouring skincare product hold marketleading position key market world product botox cosmetic botox cosmetic acetylcholine release inhibitor neuromuscular block agent indicate treatment area temporary improvement appearance moderate severe glabellar line frown line eyebrow moderate severe crow foot moderate severe forehead line adult receive initial fda approval botox cosmetic approve use major market world juvederm collection filler juvederm collection filler portfolio hyaluronic acidbased dermal filler variety approve indication major market world augment treat volume loss cheek chin lip low face aesthetic aesthetic product include limit alloderm regenerative dermal tissue coolsculpte body contouring technology natrelle breast implant skinmedica skincare line latisse eyelash solution diamondglow dermabrasion technology neuroscience product abbvie neuroscience product address difficulttotreat neurologic disease product botox therapeutic botox therapeutic onabotulinumtoxina injection acetylcholine release inhibitor neuromuscular block agent inject muscle tissue united states approve treat numerous indication include chronic migraine overactive bladder adult inadequate response anticholinergic medication urinary incontinence detrusor overactivity associate neurologic condition adult inadequate response anticholinergic medication addition botox therapeutic approve treat spasticity patient year age old cervical dystonia adult condition botox market country world license vary botox therapeutic market gsk japan vraylar vraylar cariprazine dopamine dpreferring dd receptor partial agonist hta receptor partial agonist vraylar indicate acute maintenance treatment schizophrenia adult acute treatment manic mixed episode associate bipolar disorder adult acute treatment depressive episode associate bipolar disorder adult adjunctive treatment major depressive disorder duopa duodopa carbidopa levodopa abbvie levodopacarbidopa intestinal gel treatment advanced parkinson disease market duopa united states duodopa outside united states ubrelvy ubrelvy ubrogepant calcitonin generelate peptide receptor antagonist indicate acute treatment migraine aura adult ubrelvy commercialize united states israel saudi arabia united arab emirates approve canada qulipta qulipta atogepant calcitonin generelate peptide receptor antagonist indicate preventive treatment episodic migraine adult qulipta commercialize united states recently approve use canada eye care product abbvie eye care product address unmet need new approach help preserve protect patient vision product lumiganganfort lumigan bimatoprost ophthalmic solution daily topical prostaglandin analog indicate reduction elevate intraocular pressure iop patient open angle glaucoma oag ocular hypertension oht ganfort daily topical fix combination bimatoprost timolol reduction iop adult patient oag oht lumigan sell united states numerous market world ganfort approve european union market south america middle east asia alphagancombigan alphagan brimonidine tartrate ophthalmic solution alphaadrenergic receptor agonist indicate reduction elevated iop patient openangle glaucoma ocular hypertension combigan brimonidine tartratetimolol maleate ophthalmic solution approve reduce elevated iop patient glaucoma require additional adjunctive ioplowere therapy alphagan combigan available sale united states numerous market world form krestasis restasis calcineurin inhibitor immunosuppressant indicate increase tear production patient tear production presume suppress ocular inflammation associate keratoconjunctivitis sicca restasis approve united states number market south america middle east asia eye care eye care product include ozurdex refreshoptive xen durysta key product abbvie key product include thing treatment patient hepatitis c virus hcv metabolic hormone product target number condition include exocrine pancreatic insufficiency hypothyroidism endocrinology product palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patient anemia cause uterine fibroid product mavyretmaviret mavyret glecaprevirpibrentasvir approve united states european union maviret treatment adult pediatric patient year old weigh kilogram chronic hcv genotype infection cirrhosis compensate cirrhosis childpugh indicate treatment adult pediatric patient year old weigh kilogram hcv genotype infection previously treat regiman contain hcv nsa inhibitor nsa protease inhibitor week pangenotypic treatment patient cirrhosis follow expedition study patient compensate cirrhosis new treatment creon creon pancrelipase pancreatic enzyme therapy exocrine pancreatic insufficiency condition occur patient cystic fibrosis chronic pancreatitis condition lupron lupron leuprolide acetate market lucrin lupron depot product palliative treatment advance prostate cancer treatment endometriosis central precocious puberty preoperative treatment patient anemia cause uterine fibroid lupron approve daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection linzessconstella linzess linaclotide oncedaily guanylate cyclasec agonist adult treat irritable bowel syndrome constipation ibsc chronic idiopathic constipation product market linzess united states constella outside united states synthroid synthroid levothyroxine sodium tablet usp treatment hypothyroidism abbvie right sell creon synthroid united states marketing sale distribution capability abbvie utilize combination dedicate commercial resource regional commercial resource distributorship market sell distribute product worldwide abbvie direct primary marketing effort secure prescription recommendation brand product physician external expert health care provider manage care provider example health maintenance organization pharmacy benefit manager hospital state federal government agency example state medicaid programs united states department veterans affairs united states department defense important customer abbvie market directly consumer united states company product sell pursuant prescription outside united states abbvie focus promotional market access effort external expert payer physicians health system abbvie provide patient support program closely relate product abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse certain product include aesthetic product device sell directly physician license healthcare provider abbvie business significant seasonality abbvie product revenue affect end customer retail buying pattern fluctuation wholesaler inventory level factor united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly retailer pharmacy patient customer wholesale distributor mckesson corporation cardinal health inc amerisourcebergen corporation account substantially abbvie pharmaceutical product sale united states individual wholesaler account great abbvie gross revenue united states outside united states abbvie sell product primarily wholesaler distributor depend market work largely centralized national payer system agree reimbursement term certain product comarkete copromote company abbvie single customer customer lose material adverse effect company business material portion abbvie business subject renegotiation profit termination contract election government order generally fill current basis order backlog material abbvie business competition market abbvie product highly competitive abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product therapie biologics example abbvie immunology product compete antitnf products jak inhibitor competitive product intend treat number disease state abbvie oncology product compete btk inhibitor addition past year number company start develop successfully develop andor currently market product position competitor botox search technological innovation pharmaceutical product significant aspect competition introduction new product competitor change medical practice procedure result product obsolescence price competitive factor addition substitution generic biosimilar pharmaceutical product brand pharmaceutical product create competitive pressure abbvie product patent protection new product treatment bring market abbvie competitor cause revenue abbvie product decrease price reduction sale volume decrease biosimilar competition abbvie biologic product affect approval followon biologic know biosimilar biologic add major therapeutic option treatment disease include therapy unavailable inadequate cost develop produce biologic therapy typically dramatically high small molecule medication biologic medication ongoing treatment chronic disease rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investment biologics infrastructure manufacture necessary produce biologic product humira face direct biosimilar competition europe united states countries abbvie continue face competitive pressure biologic orally administer product united states fda regulate biologics federal food drug cosmetic act ffdca public health service act phsa regulation implement statute enactment federal health care reform legislation march provide pathway approval biosimilar phsa approval process science biosimilar complex approval fda dependent factor include show biosimilar highly similar original product clinically meaningful difference original product term safety purity potency type datum ordinarily require application similarity include analytical data bioequivalence study study demonstrate chemical similarity animal study include toxicity study clinical study furthermore law provide biosimilar product determine interchangeable consider fda substitutable original biologic product intervention health care provider prescribe original biologic product prove biosimilar product interchangeable applicant demonstrate product expect produce clinical result original biologic product give patient product administer patient safety risk potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product great risk original biologic product switch law continues interpret implement fda result ultimate impact implementation mean remain subject uncertainty intellectual property protection regulatory exclusivity generally approval product entitle certain kind exclusivity applicable intellectual property regulatory regime abbvie intellectual property materially valuable company abbvie seek patent protection available significant market andor country product development united states expiration date patent year filing date give patent relate pharmaceutical product obtain early development process give time need complete clinical trial development activity require regulatory approval length time product launch patent expiration significantly year drug price competition patent term restoration act commonly know hatchwaxman act permit patent holder seek patent extension commonly call patent term restoration patent product process make product regulate ffdca length patent extension roughly base percent period time file investigational new drug application nda form kcompound submission nda compound plus percent time period nda submission regulatory approval extension exceed year patent term remain regulatory approval exceed year biological product license phsa similarly eligible term patent restoration pharmaceutical product entitle form legal regulatory exclusivity approval scope length requirement exclusivitie vary united states jurisdictions united states fda approve conventional drug product contain active ingredient previously approve product typically entitle year nonpatent regulatory exclusivity specific condition use approve individual product entitle year exclusivity approval base fdas reliance new clinical study essential approval submit nda applicant nda applicant study product use child fda grant pediatric exclusivity extend day exist exclusivitie patent regulatory relate product product treat condition afflict relatively small population reasonable expectation research development cost recover fda designate pharmaceutical orphan drug grant seven year exclusivity type regulatory exclusivity available generate new antibiotic incentive gain exclusivity provide new antibiotic new antifungal drug additional year exclusivity add certain exclusivitie provide law applicable law regulation dictate scope exclusivity product particular characteristic product entitle approval particular country certain instance regulatory exclusivity offer protection patent protection long available period time excess patent protection possible estimate product development total period scope exclusivity entitle regulatory approval obtain later give length time require complete clinical development pharmaceutical product period exclusivity achieve individual case generally expect exceed minimum year maximum year estimate consider factor difficulty recreate manufacturing process particular product proprietary knowledge delay introduction generic followon product expiration applicable patent regulatory exclusivity period biologic entitle exclusivity biologic price competition innovation act pass march title vii patient protection affordable care act law provide pathway approval biosimilar follow expiration year regulatory exclusivity innovator biologic potential additional dayextension term conduct pediatric study biologic eligible orphan drug exclusivity discuss law include extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability european union create pathway approval biosimilar publish guideline approval certain biosimilar product complex nature biologic biosimilar product lead close regulatory scrutiny followon biosimilar product reduce effect biosimilar sale innovator biologic compare sale erosion cause generic version small molecule pharmaceutical product abbvie own license right substantial number patent patent application abbvie license own patent portfolio thousand patent family include united states patent application andor issue patent contain nonunite state counterpart patent application patent application include patent expire period early aggregate believe material importance operation abbvie business abbvie believe single patent license trademark relate group patent license trademark relate adalimumab sell trademark humira material relation company business abbvie enter settlement license agreement adalimumab biosimilar manufacturer agreement license united states begin license europe begin addition follow patent license trademark significant relate ibrutinib sell trademark imbruvica relate risankizumab sell trademark skyrizi relate upadacitinib sell trademark rinvoq united states composition matter patent cover ibrutinib expect expire pediatric regulatory exclusivity extend generic entry ibrutinib product expect prior march united states composition matter patent cover risankizumab expected expire united states composition matter patent cover upadacitinib expect expire abbvie rely circumstance trade secret protect technology abbvie seek protect technology product candidate confidentiality agreement employee consultant advisor contractor collaborator agreement breached abbvie adequate remedy breach addition abbvie trade secret know independently discover competitor extent abbvie employee consultant advisor contractor collaborator use intellectual property own work company dispute arise right relate result knowhow invention license acquisition arrangement addition independent effort develop market product abbvie enter arrangement acquisition optiontoacquire agreement license arrangement optiontolicense arrangement strategic alliance copromotion arrangement codevelopment comarkete agreement joint venture acquisition optiontoacquire agreement typically include term condition nonrefundable purchase price payment option fee option exercise payment milestone earnout customary term obligation license arrangement typically include term condition nonrefundable upfront license fee option fee option exercise payment milestone payment royalty andor profit sharing obligation note license acquisition arrangementsother licensing acquisition activity consolidated financial statement include item financial statement supplementary datum party agreement abbvie agreement party process development product distribution analytical service manufacture certain product abbvie procure certain product service limit number supplier case single supply source addition abbvie agreement party active pharmaceutical ingredient product manufacturing formulation development service fill finish packaging service transportation distribution logistic service certain product abbvie believe manufacturingrelate agreement material abbvie business substantially dependent individual agreement case abbvie maintain alternate supply relationship utilize undue disruption manufacturing process party fails perform contractual obligation abbvie seek maintain sufficient inventory product minimize impact supply disruption abbvie party certain collaboration arrangement discuss note license acquisition arrangementsother licensing acquisition activity consolidated financial statement include item financial statement supplementary data source availability raw material abbvie purchase ordinary course business raw material supply essential operation numerous supplier world addition certain medical device component necessary manufacture abbvie product provide unaffiliated party supplier despite disruption global supply chain cause covid abbvie continue supply patient material supply impact previously disclose supply issue impact lupron give general increase global volatility pandemic abbvie monitoring take action mitigate potential supply shortage impact fulfillment product demand research development activity abbvie make significant investment research development numerous compound complementary device clinical development include potential treatment complex lifethreatening disease abbvie ability discover develop new compound enhance company use integrate discovery development project team include chemist biologist physician pharmacologist work compound team abbvie partner party biotechnology company pharmaceutical company academic institution identify prioritize promise new treatment complement enhance abbvie exist portfolio abbvie supplement research development effort acquisition research development process generally begin discovery research focus identification molecule desire effect give disease preclinical testing identify compound prove successful compound move clinical development generally include follow phase phase involve human test small number healthy volunteer patient assess safety tolerability dose later phase phase test different dose drug disease state order assess efficacy phase test drug demonstrate favorable result early phase significantly large patient population demonstrate efficacy safety order meet requirement enable global approval form kpreclinical datum clinical trial development phase provide datum require prepare submit nda biological license application bla submission regulatory approval fda similar government agency outside united states specific requirement eg scope clinical trial obtain regulatory approval vary different country geographic region research development process discovery new drug launch typically take year long research development new pharmaceutical product significant inherent uncertainty guarantee molecule receive regulatory approval require launch new drug indication addition development new product delivery device new formulation research development project include phase trial call postmarkete study project clinical trial design conduct collect additional datum parameter benefit risk approve drug regulationdiscovery clinical development united states secure approval market new pharmaceutical product united states require substantial effort financial resource take year complete applicant complete preclinical test submit protocol fda commence clinical trial clinical trial intend establish safety efficacy pharmaceutical product typically conduct sequential phase phase overlap combine require clinical testing successful result submit fda form nda bla request approval market product indication fda review nda bla determine product safe effective intended use manufacturing compliant current good manufacturing practice cgmp compliance regulatory requirement assure periodic announce unannounced inspection fda regulatory authority inspection associate clinical development include sponsor investigator site laboratory hospital manufacture facility abbvie subcontractor thirdparty manufacturer failure comply applicable regulatory requirement result enforcement action fda include rejection nda bla nda bla receive approval applicant comply postapproval requirement example holder approval report adverse reaction provide update safety efficacy information comply requirement concern advertise promotional material activity quality control manufacturing procedure continue conform cgmp approval certain change manufacturing procedure finish product submitted approve fda prior implementation fda periodically inspect manufacture facility assess compliance cgmp impose extensive procedural record keeping requirement addition condition approval fda require postmarkete testing surveillance assess monitor product safety efficacy commercialization require additional clinical trial patient registry observational datum additional work chemistry manufacturing control postapproval regulatory obligation cost comply obligation expand future fda continue regulate product labeling prohibit promotion product unapproved offlabel use label restriction outside united states abbvie subject similar regulatory requirement outside united states approval marketing pharmaceutical product abbvie obtain approval clinical trial application product applicable supervise regulatory authority commence clinical trial marketing product target market approval requirement process country vary time require obtain approval long shorter require fda approval united states example abbvie submit marketing authorization european union centralize decentralize procedure centralize procedure mandatory approval biotechnology product pharmaceutical product provide single marketing authorization valid european union member state centralized procedure single marketing authorization application submit european medicine agency agency evaluate application make recommendation european commission make final determination approve application decentralize procedure provide mutual recognition individual national approval decision available product subject centralized procedure japan application approval new product pharmaceutical medical device agency pmda japanspecific trial andor bridge study demonstrate nonjapanese clinical datum apply japanese patient require complete comprehensive review pmda report ministry health labour welfare approve deny application similarly application new product china submit center drug evaluation national medical product administration technical review approval product marketing china clinical datum chinese subject usually require support approval china require inclusion china global pivotal study separate chinaasian clinical trial regulatory process emerge market continue evolve emerge market include asia generally require regulatory approval obtain large develop market united states europe country begin complete regulatory review process similar requirement japan china certain country notably south korea taiwan india russia generally require clinical study include data patient country conduct order support local regulatory approval requirement govern conduct clinical trial product licensing vary addition postapproval regulatory obligation adverse event report cgmp compliance generally apply vary country example marketing authorization grant european union periodic safety report submit pharmacovigilance measure require risk management plan regulationcommercialization distribution manufacturing manufacturing marketing sale promotion distribution abbvie product subject comprehensive government regulation government regulation national regional federal state local agency united states country address matter inspection control research laboratory procedure clinical investigation product approval manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarkete surveillance record keeping storage disposal practice abbvie operation affect trade regulation country limit import raw material finish product law regulation seek prevent corruption bribery marketplace include united states foreign corrupt practice act united kingdom bribery act provide guidance corporate interaction government official require safeguard protection personal datum addition abbvie subject law regulation pertain health care fraud abuse include state federal antikickback false claim law united states prescription drug manufacturer abbvie subject taxis application product user fee compliance law regulation costly materially affect abbvie business effect health care regulation substantially increase time difficulty cost incur obtain maintain approval market newly develop exist product abbvie expect compliance regulation continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement action seizure recall product suspension revocation authority necessary product production sale civil criminal sanction include fine penalty addition regulatory initiative abbvie business affect ongoing study utilization safety efficacy outcomes health care product component regularly conduct industry participant government agency study lead update datum utilization safety efficacy previously market product case study result future result discontinuance limitation marketing product domestically worldwide rise claim damage person believe injure result use access human health care product continue subject oversight investigation action governmental agency legislative body private organization united states country major focus cost containment effort reduce health care cost private sector notably health care payer provider institute cost reduction containment measure abbvie expect insurer provider continue attempt reduce cost health care product outside united states country control price health care product directly indirectly reimbursement payment pricing coverage limitation compulsory license political budgetary pressure united states country heighten scope severity pricing pressure abbvie product foreseeable future united states specifically federal law require pharmaceutical manufacturer pay certain statutorilyprescribe rebate state medicaid programs prescription drug reimburse state medicaid plan effort state seek additional rebate affect abbvie business similarly veteran health care act prerequisite participation medicaid federal health care program require manufacturer extend additional discount pharmaceutical product federal agency include united states department veterans affairs department defense public health service entity institution addition recent legislative change require similarly discount price offer tricare program beneficiary veterans health care form kact establish b drug discount program require pharmaceutical manufacturer provide product reduce price designate health care entity facilities united states states generic substitution legislation require permit dispense pharmacist substitute different manufacturer generic version pharmaceutical product prescribe addition federal government follows diagnosisrelate group drg payment system certain institutional service provide medicare medicaid implement prospective payment system pps service deliver hospital outpatient nursing home home health setting drg pps entitle health care facility fix reimbursement base diagnosis andor procedure actual cost incur patient treatment increase incentive facility limit control expenditure health care product medicare reimburse b drug base average sale price plus certain percentage account physician administration cost reduce hospital outpatient set medicare enter contract private plan negotiate price patient administer medicine deliver patient protection affordable care act health care education reconciliation act affordable care act abbvie pay fee relate pharmaceutical sale government program addition abbvie provide discount brand prescription drug sell patient fall medicare coverage gap donut hole affordable care act include provision know physician payment sunshine act require manufacturers drug biologics cover medicare medicaid record transfer value physician teach hospital report datum center medicare medicaid services subsequent public disclosure similar reporting requirement enact state level united states increase number country worldwide adopt consider similar law require disclosure interaction health care professional failure report appropriate datum result civil criminal fine andor penalty european union european union adopt directive legislation govern label advertising distribution supply pharmacovigilance marketing pharmaceutical product legislation provide mandatory standard european union permit member states supplement standard additional regulation european government regulate pharmaceutical product price control national health care system fund large cost product consumer result patient unlikely use pharmaceutical product reimburse government european country government regulate price new product launch subsequent launch direct price control reference pricing recent year country impose new additional cost containment measure pharmaceutical product difference national pricing regime create price differential european union lead significant parallel trade pharmaceutical product government promote generic substitution mandate permit pharmacist substitute different manufacturer generic version pharmaceutical product prescribe permit mandate health care professional prescribe generic version certain circumstance government follow similar path biosimilar therapy addition government use reimbursement list limit pharmaceutical product eligible reimbursement national health care systems japan japan national health insurance system maintain drug price list specify pharmaceutical product eligible reimbursement ministry health labour welfare set price product list government generally introduce price cut round year mandate price decrease specific product new product judge innovative useful indicate pediatric use target orphan small population disease eligible pricing premium government promote use generic available emerge market emerge market step reduce pharmaceutical product price case direct price control promotion genericbiosimilar alternative brand pharmaceutical abbvie market product worldwide certain product local nature variation product line meet local regulatory requirement certain additional risk inherent conduct business outside united states include price currency exchange control change currency exchange rate limitation participation local enterprise expropriation nationalization governmental action regulation medical device medical device subject regulation fda state agency foreign government health authority fda regulation federal state law govern development clinical testing manufacturing labeling record keeping market medical device product agency united states abbvie medical device product candidate include abbvie breast implant undergo rigorous clinical testing extensive government regulatory clearance approval process prior sale united states countries lengthy process clinical development submission clearance approval continue need compliance applicable law regulation require expenditure substantial resource regulatory clearance approval obtain limited scope significantly limit indicate use product market clear approve product manufacturer subject ongoing review discovery previously unknown problem product result restriction manufacture sale andor use require withdrawal market united states abbvie medical device product subject extensive regulation fda united states exemption apply medical device abbvie market united states k clearance premarket approval application pma accordance ffdca implement regulation fda classifie medical device class depend degree risk associate medical device extent control need ensure safety effectiveness device deem pose low risk place class class ii device deem fda pose great risk lifesustaine lifesupporte implantable device device deem substantially equivalent previously clear k device place class iii general class iii device market united states fda approve device submission pma change device subsequent initial fda approval review approve fda majority abbvie medical device product include abbvie breast implant regulate class iii medical device class iii device significant additional obligation impose condition approval time take obtain approval long compliance regulatory requirement assure periodic unannounced facility inspection fda regulatory authority inspection include manufacture facility abbvie subcontractor thirdparty manufacturer failure comply applicable regulatory requirement result enforcement action fda include follow sanction warning letter untitled letter fine injunction civil penalty recall seizure abbvie product operate restriction partial suspension total shutdown production refuse abbvie request k clearance pma approval new product withdraw k clearance pma approval grant criminal prosecution clinical trial require support pma application require k premarket notification clinical trial generally require submission application investigational device exemption ide support appropriate data animal laboratory testing result show safe test device human test protocol scientifically sound study sponsor obtain approval ide fda obtain approval study institutional review board oversee trial result clinical testing sufficient obtain approval investigational device device approve manufacture distribution device remain subject continue regulation fda include quality system regulation requirement involve design testing control documentation quality assurance procedure manufacturing process medical device manufacturer subcontractor require register establishment list manufacture device fda subject periodic unannounced inspection fda certain state agency compliance regulatory requirement manufacturer report fda device cause contribute death injury malfunction way likely cause contribute death injury manufacturer conduct field correction product recall removal reduce risk health pose device remedy violation ffdca present health risk fda continue regulate device labeling prohibit promotion product unapproved label use label restriction european union medical device product market european union comply requirement medical device regulation mdr come effect mdr provide regulatory oversight respect design manufacture clinical trial label adverse event report medical device ensure medical device market european union safe effective intended use medical device comply mdr entitle bear conformit europenne mark evidencing compliance marketed european union failure comply domestic international regulatory requirement affect abbvie ability market sell abbvie product country form kenvironmental matter abbvie believe operation comply material respect applicable law regulation concern environmental protection regulation federal state environmental law impose stringent limitation emission discharge environment manufacturing operation abbvie capital expenditure pollution control approximately million operating expenditure approximately million capital expenditure pollution control estimate approximately million operating expenditure estimate approximately million abbott identify potentially responsible party investigation andor remediation location united states include puerto rico comprehensive environmental response compensation liability act commonly know superfund location transfer abbvie connection separation distribution abbvie party investigation remediations abbott engage remediation site transfer abbvie connection separation distribution cooperation environmental protection agency similar agency feasible predict certainty final cost relate investigation remediation activity abbvie believe cost expenditure maintain compliance applicable law regulation concern environmental protection material adverse effect company financial position cash flow result operation employee abbvie employ approximately employee country january outside united states abbvie employee represent union work council abbvie believe good relation employee human capital management attract retaining provide meaningful growth development opportunity abbvie employee critical company success make remarkable impact people live world abbvie leverage numerous resource identify enhance strategic leadership capability foster employee engagement create culture diverse talent productive engage abbvie invest employee competitive compensation benefit employee support program offer bestinclass development leadership opportunity abbvie develop deep talent base ongoing investment functional leadership training source worldclass external talent ensure sustainable talent pipeline abbvie continuously cultivate enhance work culture embrace equality diversity inclusion fundamental company mission attract develop talent attract develop highperforming talent essential abbvie continue success abbvie implement detailed talent attraction strategy emphasis stem skill set diverse talent base critical skillset include drug discovery clinical development market access business development abbvie invest integrate inclusive practice endtoend hire process introduce inclusive recruitment live training requirement people leader recruiter abbvie invest competitive compensation benefit program addition offer comprehensive suite benefit range medical dental coverage retirement disability life insurance programs abbvie provide health promotion program mental health awareness campaign employee assistance program country financial wellness support onsite health screening immunization country onsite fitness rehabilitation center abbvie launch onsite health care clinic certain location offer convenient affordable access quality healthcare flu shot vaccine addition abbvie employee assistance fund abbvie foundation support program global employee abbvie possibility scholarship child employee annual meritbase scholarship use accredited college university vocationaltechnical school employee relief program financial assistance support short term need employee face largescale disaster eg hurricane individual disaster eg home fire financial hardship eg death spouse finally abbvie empower manager team tool tip guideline effectively manage workload manage team distance support flexible work practice implement work abbvie hybrid work model offer eligible employee predictable flexibility new abbvie employee give tailored onboarding experience fast integration support performance abbvie mentorship program allow employee selfnominate mentor mentee facilitate meaningful relationship support employee career development goal abbvie provide structure broadbase development opportunity focus highperformance skill leadership training abbvie talent philosophy hold leader accountable building highperforming organization company provide development opportunity level leadership abbvie learn develop perform program offer yearlong selfdirecte leadership education supplement tool resource leverage leader role model teacher addition foundational success factor abbvie leadership pipeline company professional development program attract graduate postgraduate postdoctoral talent participate formal development program last year objective strengthen functional leadership capability culture abbvie share value transform live act integrity drive innovation embrace diversity inclusion serve community form core company culture abbvie articulate behavior associate value way work core set working behavior emphasize company achieve result equally important achieve way work design ensure abbvie employee aware company cultural expectation abbvie integrate way work talent process form basis assess performance prioritize development ultimately reward employee abbvie believe culture create strong engagement measure regularly confidential thirdparty allemployee survey engagement support abbvie mission make remarkable impact people live equity equality diversity inclusion eedi cornerstone abbvie human capital management approach prioritize foster inclusive diverse workforce recently abbvie adopt fiveyear equality diversity inclusion roadmap define key global focus area objective associate initiative include implementation plan organize business function geography abbvie senior leader adopt formal goal align execute strategy recent year abbvie board director prioritize oversight abbvie response racial justice movement include oversee internal program design ensure abbvie attract retain develop diverse talent december woman represent percent management position globally united states percent abbvie workforce comprise member historically underrepresented population increase abbvie commit pay equity conduct pay equity analysis annually critical component abbvie strategy instill inclusive mindset abbvie leader employee company continue realize value diverse workforce recruitment retirement abbvie employee resource group help company nurture inclusive culture building community create connection opportunity mentor professional development talent attraction network abbvie reiterate commitment racial equality social justice thing expand employee matching program donation civil right nonprofit foster racial equity reaffirming commitment clinical trial diversity additional information abbvie effort racial equality social justice provide company website httpsabbviecomourcompanyequalityinclusiondiversityourcommitmenttoracialjusticehtml internet information copy abbvie annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act available free charge abbvie investor relation website investorsabbviecom soon reasonably practicable abbvie electronically file material furnish securities exchange commission sec abbvie corporate governance guideline outline directorship qualification code business conduct charters abbvie audit committee compensation committee nomination governance committee public policy committee available abbvie investor relation website investorsabbviecom item risk factor carefully consider follow risk information evaluate abbvie abbvie common stock follow risk materially adversely affect abbvie result operation financial condition cash flow risk factor generally separate group risk relate abbvie business risk relate abbvie common stock base information currently know abbvie believe follow information identify significant risk factor affect category risk risk uncertainty abbvie face limit set forth risk factor describe order importance probability occurrence additional risk uncertainty presently know abbvie abbvie currently believe immaterial adversely affect business addition past financial performance reliable indicator future performance historical trend anticipate result trend future period form kif follow risk uncertainty develop actual event event material adverse effect abbvie business result operation financial condition cash flow case trading price abbvie common stock decline risk relate abbvie business expiration loss patent protection license include loss exclusivity humira increase competition biosimilar adversely affect abbvie revenue operate earning abbvie rely patent trademark intellectual property protection discovery development manufacturing sale product particular patent protection aggregate important abbvie marketing pharmaceutical product united states major market outside united states patent cover abbvie product normally provide market exclusivity important profitability abbvie product patent certain product expire abbvie face competition lower price generic biosimilar product expiration loss patent protection product typically follow promptly substitute significantly reduce sale product short time abbvie competitive position compromise generic biosimilar material adverse effect abbvie business result operation addition proposal emerge time time legislation encourage early rapid approval generic drug biosimilar proposal enact law increase impact generic competition large pharmaceutical company generic manufacturers pharmaceutical product continue expand biotechnology field form partnership pursue biosimilar company develop develop biosimilar compete abbvie biologic product include humira competitor obtain marketing approval biosimilar reference abbvie biologic product abbvie product subject competition biosimilar attendant competitive pressure consequence expiration successful challenge abbvie applicable patent right trigger competition product assume relevant exclusivity period expire result abbvie face increase litigation administrative proceeding respect validity andor scope patent relate biologic product example humira account approximately abbvie total net revenue humira face competition biosimilar product united states begin loss exclusivity abbvie anticipate cause significant decline humira revenue adversely affect abbvie revenue operate earning abbvie principal patent trademark describe great detail item businessintellectual property protection regulatory exclusivity item management discussion analysis financial condition result operationsresult operation litigation patent describe item legal proceeding abbvie major product lose patent protection early expect adversely affect abbvie revenue operate earning significant portion abbvie revenue operating earning derive major product party government authority challenge seek invalidate circumvent abbvie patent patent application example manufacturer generic pharmaceutical product file continue file abbreviate new drug application fda seek market generic form abbvie product prior expiration relevant patent own license abbvie assert patent invalid unenforceable andor infringe addition petitioner file continue file challenge validity abbvie patent leahysmith america invents act create inter parte review post grant review procedure challenge patent validity administrative proceeding united states patent trademark office challenge abbvie intellectual property come business government challenge intellectual property right example court decision potential legislation relate patent legislation biosimilar regulatory initiative result erosion intellectual property protection addition certain government outside united states indicate compulsory license patent seek domestic policy basis national emergency hivaid trigger compulsory license diminish eliminate sale profit jurisdiction negatively affect abbvie result operation abbvie normally respond challenge vigorously defend patent include file patent infringement lawsuit patent litigation administrative proceeding challenge abbvie patent costly unpredictable deprive abbvie market exclusivity patent product extent abbvie intellectual property successfully challenge circumvent weakened extent intellectual property allow abbvie compete effectively abbvie business suffer extent country enforce abbvie intellectual property right require compulsory licensing abbvie intellectual property abbvie revenue operate earning reduce party intellectual property prevent abbvie selling product material adverse effect abbvie profitability financial condition party claim abbvie product infringe intellectual property addition pursuit valid business opportunity abbvie require challenge intellectual property right hold believe improperly grant resolve intellectual property infringement claim costly time consuming require abbvie enter license agreement abbvie guarantee able obtain license agreement commercially reasonable term successful claim patent intellectual property infringement subject abbvie significant damage injunction prevent manufacture sale use affect abbvie product product event material adverse effect abbvie profitability financial condition abbvie research development effort succeed develop marketing commercially successful product technology cause revenue profitability decline remain competitive abbvie continue launch new product new indication andor brand extension exist product launch generate revenue sufficient cover substantial research development cost replace revenue profitable product lose displace compete product therapy failure material adverse effect abbvie revenue profitability accordingly abbvie commit substantial effort fund resource research development ongoing substantial expenditure assurance effort commercially successful high rate failure biopharmaceutical industry inherent research development new product failure occur point research development process include significant fund invest product appear promise development fail reach market numerous reason include failure demonstrate effectiveness safety concern superior safety efficacy compete therapy failure achieve positive clinical preclinical outcome current standard care inability obtain necessary regulatory approval delay approval new product new indication limited scope approve use excessive cost manufacture failure obtain maintain intellectual property right infringement intellectual property right decision research study early development process pharmaceutical product candidate affect marketing strategy candidate receive approval detailed study demonstrate additional benefit help marketing consume time resource delay submit pharmaceutical product candidate regulatory approval abbvie guarantee proper balance speed testing respect pharmaceutical product candidate decision area adversely affect abbvie result operation abbvie successfully develop market new product enhancement exist product quickly render obsolete change clinical preference change industry standard competitor innovation abbvie innovation accept quickly marketplace exist clinical practice uncertainty thirdparty reimbursement abbvie state certainty product development launch able develop license acquire compound product product commercially successful failure launch successful new product new indication exist product cause abbvie product obsolete cause abbvie revenue operating result suffer abbvie subject costcontainment effort pricing pressure cause reduction revenue operate earning change term rebate chargeback programs common pharmaceutical industry material adverse effect abbvie operation costcontainment effort government private organization describe great detail item businessregulationcommercialization distribution manufacturing extent cost containment effort offset great demand increase patient access health care factor abbvie revenue operate earning reduce united states european union country abbvie business experience downward pressure product pricing pressure increase future abbvie subject increase public legislative pressure respect pharmaceutical pricing united states practice manage care group institutional governmental purchaser federal law regulation relate medicare medicaid contribute pricing pressure particular inflation reduction act form k require government negotiate price select high expenditure medicare drug price effective begin b drug price effective begin ii manufacturer pay rebate medicare b drug price drug increase fast inflation begin b iii medicare redesign replace current coverage gap provision establish cap outofpocket cost medicare beneficiary begin manufacturer responsible cost cap cap reach inflation reduction act implement forthcoming agency action outcome reasonably determine certainty additionally change tax law require minimum tax generally apply corporation adjust financial statement income begin ii nondeductible excise tax provision net stock repurchase apply repurchase begin abbvie continue evaluate impact inflation reduction act company potential continue change health care system united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result additional pricing pressure major market worldwide government play significant role fund health care service determine pricing reimbursement pharmaceutical product consequently market abbvie subject government decisionmake budgetary action respect product particular european country ongoing governmentmandate price reduction pharmaceutical product abbvie anticipate continue pricing pressure europe difference country pricing regulation lead thirdparty crossborder trading abbvie product result reduction revenue operate earning rebate relate government program feeforservice medicaid medicaid manage care program arise law regulation abbvie predict certainty additional government initiative contain health care cost factor lead new modify regulatory requirement include high incremental rebate discount rebate discount program arise contractual agreement private payer factor include market factor ability private payer control patient access product provide payer leverage negotiate high additional rebate discount material adverse effect abbvie operation portion abbvie nearterm pharmaceutical pipeline rely collaboration party adversely affect development sale product abbvie depend alliance joint venture pharmaceutical biotechnology company portion product nearterm pharmaceutical pipeline failure party meet contractual regulatory obligation abbvie disruption relationship abbvie party adverse effect abbvie pharmaceutical pipeline business addition abbvie collaborative relationship research development extend year rise dispute relative right obligation revenue abbvie collaboration partner include ownership intellectual property associate right obligation result loss intellectual property right protection delay development sale potential pharmaceutical product affect effective sale delivery abbvie commercialize product lead lengthy expensive litigation administrative proceeding arbitration biologic carry unique risk uncertainty negative impact abbvie business result operation successful discovery development manufacturing sale biologic long expensive uncertain process unique risk uncertainty biologic example access supply necessary biological material cell line limit current governmental regulation restrict access regulate transport use material addition development manufacturing sale biologic subject regulation complex extensive regulation applicable pharmaceutical product result manufacture biologic especially large quantity complex require use innovative technology manufacturing require facility specifically design validate purpose sophisticated quality assurance quality control procedure biologic frequently costly manufacture production input derive live animal plant material biologic synthetically failure successfully discover develop manufacture sell biologicsinclude humira skyrizi negative impact abbvie business result operation new product technological advance abbvie competitor negatively affect abbvie result operation abbvie compete researchbase pharmaceutical biotechnology company research develop manufacture market sell proprietary pharmaceutical product biologic example humira compete anti tnf product competitive product intend treat number disease state mavyretmaviret competes available hepatitis c treatment option addition past year number company start develop successfully develop andor currently market product position competitor botox competitor introduce new product develop technological advance compete abbvie product therapeutic area immunology hematologic oncology aesthetic neuroscience eye care addition abbvie product lose exclusivity competition surround product increase generic biosimilar product increasingly penetrate market abbvie predict certainty timing impact introduction competitor new product technological advance compete product safer effective effectively market sell low price well insurance coverage reimbursement level superior performance feature abbvie product negatively impact abbvie business result operation manufacture abbvie product highly exact complex process abbvie supplier encounter problem manufacture abbvie product abbvie business suffer manufacture abbvie product highly exact complex process strict regulatory requirement problem arise manufacturing variety reason include equipment malfunction failure follow specific protocol procedure problem raw material delay relate construction new facility expansion exist facility include intended support future demand abbvie product change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation inhibit continuous supply manmade natural disaster environmental factor problem arise production batch product batch product discard abbvie experience product shortage incur add expense thing lead increase cost lose revenue damage customer relation time expense spend investigate cause depend cause similar loss respect batch product problem discover product release market recall product liability cost incur abbvie use raw material component pharmaceutical biologic manufacturing process include source single supplier interruption supply raw material component adversely affect abbvie business result operation abbvie use raw material component pharmaceutical biologic manufacturing process source single supplier failure abbvie supplier particularly singlesource supplier fulfill contractual obligation timely manner result regulatory noncompliance physical disruption manufacturing site impair abbvie ability deliver product customer timely competitive basis adversely affect abbvie business result operation increase demand abbvie supplier result delay disruption manufacture distribution sale product andor product shortage lead lose revenue find alternative supplier significant time involve significant expense nature product need obtain regulatory approval abbvie guarantee able reach agreement alternative provider regulatory authority approve abbvie use alternative business interruption insurance provide adequate compensation case failure supplier certain aspect abbvie operation highly dependent party service provider abbvie rely supplier vendors party service provider research develop manufacture commercialize promote sell product reliance party manufacturer reduce abbvie oversight control manufacturing process party provider subject legal regulatory requirement privacy security risk market risk failure critical party service provider meet obligation material adverse impact abbvie operation result party service provider violate allege violate law regulation performance obligation abbvie possible abbvie suffer financial reputational harm negative outcome include possible legal consequence significant safety efficacy issue arise abbvie product material adverse effect abbvie revenue financial condition pharmaceutical product receive regulatory approval base datum obtain control clinical trial limit duration follow regulatory approval product long period time patient additional extensive study conduct sponsor abbvie sponsor competitor insurance company government institution scientist investigator interested party new safety efficacy issue report new scientific information available include result postmarkete phase trial government change standard safety efficacy labeling abbvie require amend form kthe condition use product example abbvie voluntarily provide require provide update information product label narrow approve indication reduce product market acceptance safety efficacy issue abbvie product arise sale product halt abbvie regulatory authority regulatory action take regulatory authority safety efficacy issue affect supplier competitor product reduce market acceptance similar abbvie product new data abbvie product product similar product negatively impact demand abbvie product actual perceive safety issue uncertainty efficacy case result product withdrawal furthermore new data information include information product misuse lead government agency professional society practice management group organization involve disease publish guideline recommendation relate use abbvie product use related therapy place restriction sale guideline recommendation lead low sale abbvie product abbvie subject product liability claim lawsuit adversely affect business result operation reputation ordinary course business abbvie subject product liability claim lawsuit allege abbvie current historical product product company promote result result unsafe condition injury patient example lawsuit pende allergan abbvie subsidiary certain officer allege misrepresentation omission allergan texture breast implant product liability claim lawsuit safety alert product recall regardless ultimate outcome material adverse effect abbvie business result operation reputation ability attract retain customer consequence include additional cost decrease market share product question low revenue exposure claim abbvie evaluate risk determined cost obtain product liability insurance outweighs likely benefit coverage available abbvie product liability loss selfinsure abbvie subject claim legal proceeding investigation ordinary course business relate intellectual property commercial security matter adverse outcome claim legal proceeding investigation adversely affect abbvie business result operation reputation example allergan name defendant approximately matter relate promotion sale prescription opioid pain reliever allergan recently agree nationwide settlement resolve matter provide billion help support state local effort address opioidrelate issue unite states thing abbvie guarantee condition settlement satisfied additional suit file note legal proceeding contingency consolidated financial statement include item financial statement supplementary data abbvie predict certainty outcome proceeding abbvie subject governmental regulation costly comply regulation develop compliant product process abbvie product subject rigorous regulation numerous international supranational federal state authority describe item businessregulationdiscovery clinical development businessregulationcommercialization distribution manufacturing business regulationmedical device process obtain regulatory approval market pharmaceutical product costly time consume approval grant future product additional indication use exist product timely basis delay receipt failure obtain approval future product new indication use result delay realization product revenue reduction revenue substantial additional cost healthcare industry particular highly regulate subject frequent substantial regulatory change expect healthcare industry continue subject increase regulation political legal action future proposal reform healthcare system consider executive branch congress state legislature abbvie predict certainty additional change healthcare industry general pharmaceutical industry particular occur impact change example inflation reduction act implement forthcoming agency action outcome reasonably determine certainty addition abbvie guarantee remain compliant applicable regulatory requirement approval obtain product requirement include thing regulation manufacturing practice product label advertising postmarkete reporting include adverse event report field alert manufacturing quality concern abbvie incur expense spend time effort ensure compliance complex regulation possible regulatory action result substantial modification abbvie business practice operation refund recall seizures abbvie product total partial shutdown production abbvie supplier facility abbvie supplier remedy allege violation inability obtain future approval withdrawal suspension current product market event disrupt abbvie business material adverse effect business result operation law regulation affect government benefit program impose new obligation abbvie require change business practice restrict operation health care industry subject federal state international law regulation pertain government benefit program reimbursement rebate price reporting regulation health care fraud abuse united states law include antikickback false claim law medicaid rebate statute veterans health care act physician payment sunshine act tricare program government pricing rule applicable medicaid medicare b b drug pricing program individual state law relate pricing sale marketing practice violation law regulation punishable criminal andor civil sanction include instance substantial fine imprisonment exclusion participation federal state health care program include medicare medicaid veterans administration health program violation lead product recall seizure interruption production lead product shortage import ban denial import certification delay denial approval new product supplemental approval current product pende resolution issue reputational harm adversely affect abbvie business law regulation broad scope subject change evolving interpretation require abbvie incur substantial cost associate compliance alter sale marketing practice addition violation law regulation allegation violation impose new obligation abbvie require change business practice restrict operation public health outbreak epidemic pandemic coronavirus covid future adverse impact abbvie operation financial condition public health outbreak epidemic pandemic future adverse impact abbvie operation financial condition pandemic cause novel strain coronavirus covid cause country include united states declare national emergency implement preventive measure travel ban shelter place total lockdown order continuation reimplementation ban order remain uncertain covid pandemic cause abbvie modify certain business practice abbvie action require government authority abbvie determine good interest abbvie employee patient customer business partner impact covid abbvie operation include manufacture supply chain sale marketing commercial clinical trial operation date material abbvie experience low new patient start certain product market impact covid public health outbreak abbvie longterm uncertain predict confidence extent adverse impact covid public health outbreak abbvie operation depend extent severity continue spread disease globally time nature action take respond result economic consequence ultimately effort mitigate impact covid public health outbreak completely prevent abbvie business adversely affect future impact remain uncertain international nature abbvie business subject additional business risk cause revenue profitability decline abbvie business subject risk associate business internationally include emerge market net revenue outside united states approximately abbvie total net revenue risk associate abbvie operation outside united state include fluctuation currency exchange rate change medical reimbursement policy program price restriction multiple legal regulatory requirement subject change restrict abbvie ability manufacture market sell product differ local product preference product requirement trade protection measure import export licensing requirement international trade disruption dispute difficulty establish staffing manage operation differ labor regulation potentially negative consequence changes interpretation tax law political economic instability include result covid pandemic sovereign debt issue price currency exchange control limitation participation local enterprise expropriation nationalization governmental action regulation inflation recession fluctuation interest rate restriction transfer fund potential deterioration economic position credit quality certain nonus country potential penalty adverse consequence violation anticorruption antibribery similar law regulation include united states foreign corrupt practice act united kingdom bribery act particular february armed conflict escalate russia ukraine response thereto united states north atlantic treaty organization member state certain nonmember state announce target economic sanction embargo export control russia belarus abbvie continue supply essential pharmaceutical product russia humanitarian reason work maintain compliance evolve international sanction suspend operation aesthetic product russia abbvie operation russia belarus ukraine significant possible predict certainty continue consequence conflict addition sanction include regional instability geopolitical shift adverse effect macroeconomic condition currency exchange rate financial market consequence adverse impact abbvie business result operation abbvie effectively profitably commercialize product abbvie revenue financial condition adversely affect abbvie effectively profitably commercialize principal product create meeting continue market demand achieve market acceptance generating product sale ensure active pharmaceutical ingredient product finished product manufacture sufficient quantity compliance requirement fda similar foreign regulatory agency acceptable quality pricing meet commercial demand ensure entire supply chain efficiently consistently deliver abbvie product customer commercialization abbvie product successful thing unexpected challenge competitor new safety issue concern report impact narrow approve indication relative price abbvie product compare alternative treatment option change product label restrict marketing commercialization abbvie principal product unsuccessful abbvie revenue financial condition adversely affect abbvie acquire business license right technology product form alliance dispose asset cause incur significant expense negatively affect profitability abbvie pursue acquisition technology licensing arrangement joint venture strategic alliance dispose asset business strategy abbvie complete transaction timely manner costeffective basis realize expect benefit abbvie successful making acquisition product technology acquire successful require significantly great resource investment originally anticipate abbvie able integrate acquisition successfully exist business incur assume significant debt unknown contingent liability abbvie experience negative effect report result operation acquisition dispositionrelate charge amortization expense relate intangible charge impairment longterm asset effect cause deterioration abbvie credit rating result increase borrowing cost interest expense additionally change abbvie structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance joint venture restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate abbvie dependent wholesale distributor distribution product united states accordingly business result operation adversely affect encounter financial difficulty wholesale distributor mckesson corporation cardinal health inc amerisourcebergen corporation account substantially abbvie pharmaceutical product sale united states significant wholesale distributor encounter financial difficulty distributor decrease business abbvie abbvie unable collect amount distributor owe timely basis adversely affect abbvie business result operation abbvie debt obligation adversely affect business ability meet obligation debt abbvie incur intend incur important consequence abbvie investor consequence include thing require portion abbvie cash flow operation interest payment debt reduce cash flow available fund capital expenditure corporate purpose grow abbvie business extent abbvie incur additional indebtedness interest rate increase risk increase addition abbvie cash flow operation sufficient repay outstanding debt abbvie able borrow money sell asset raise fund acceptable term refinance debt abbvie need additional financing future meet capital need opportunistic acquisition financing available favorable term abbvie need additional financing future meet capital need opportunistic acquisition example need increase investment research development activity capital credit market experience extreme volatility disruption lead uncertainty liquidity issue borrower investor abbvie unable obtain desire additional financing term favorable abbvie lose investment grade credit rating adequate fund available acceptable term abbvie unable fund expansion successfully develop enhance product respond competitive pressure negatively affect abbvie business abbvie raise additional fund issue debt enter credit facility subject limitation operation restrictive covenant failure comply covenant adversely affect abbvie business abbvie depend information technology failure significant disruption system material adverse effect abbvie business abbvie rely sophisticated software application complex information technology system operate business vulnerable malicious intrusion random attack loss datum privacy disruption degradation breakdown datum privacy security breach employee future result failure critical business operation breach cause sensitive datum include intellectual property trade secret personal information belong abbvie patient customer business partner expose unauthorized person public date abbvie business operation materially impact incident abbvie invest protection datum information technology monitor system ongoing basis assurance effort prevent material breakdown breaches abbvie information technology system material adverse effect abbvie business adverse consequence include loss revenue loss critical sensitive information abbvie thirdparty provider database system result legal financial reputational business harm abbvie potentially substantial remediation cost addition abbvie maintain cyber insurance guarantee insurance sufficient cover financial legal business reputational loss result interruption breach abbvie system abbvie balance intangible asset include developed product right goodwill acquire subject impairment testing result impairment charge adversely affect abbvie result operation financial condition significant abbvie total asset relate acquire intangible goodwill december carry value abbvie develop product right intangible asset billion carrying value abbvie goodwill billion abbvie develop product right state cost accumulate amortization abbvie determine original fair value amortization period develop product right base assessment factor impact estimate form kuseful live cash flow acquire product significant adverse change factor require abbvie perform impairment test affect asset evidence impairment exist require abbvie impairment charge respect asset asset impair abbvie adjust remain useful life charge adversely affect abbvie result operation financial condition abbvie significant intangible asset include inprocess research development iprd intangible project acquire recent business combination indefinitelive intangible asset iprd asset risk failure significant certainty asset ultimately yield successful product abbvie ability realize value significant investment contingent thing regulatory approval market condition iprd asset impaired andor write point future associate research development effort abandon curtail goodwill abbvie iprd intangible asset test impairment annually event occur circumstance change potentially reduce fair value report unit intangible asset impairment testing compare fair value report unit intangible asset carrying goodwill iprd impairment record operating income material adverse effect abbvie result operation financial condition failure attract develop retain highly qualified personnel affect abbvie ability successfully develop commercialize product abbvie success largely dependent continue ability attract develop retain diverse highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel biopharmaceutical field intense increase abbvie sure able attract retain quality personnel cost materially increase illegal distribution sale party counterfeit unregistered version abbvie product material adverse impact reputation business result operation party illegally obtain distribute sell counterfeit illegally divert intended market version abbvie product version product meet abbvie rigorous manufacturing testing distribution quality standard patient receive counterfeit steal divert drug risk number dangerous health consequence prevalence counterfeitdiverte medicine industrywide issue variety factor include adoption ecommerce increase covid pandemic greatly enhance consumer ability obtain prescription medical treatment internet lieu traditional brick mortar pharmacy expose patient great risk internet prefer vehicle dangerous counterfeitdiverte product offer scam anonymity affords abbvie reputation business suffer harm result counterfeit divert drug sell brand result reduced revenue negatively affect result operation factor material adverse effect abbvie profitability financial condition factor affect abbvie result operation cash flow financial condition include change interpretation law regulation include change accounting standard taxation requirement product marketing application standard datum privacy law particularly european union united states environmental law difference fair value measurement asset liability actual value particularly pension postemployment benefit stockbase compensation intangible goodwill contingent liability litigation contingent consideration absence record record minimum compare actual change rate inflation include cost raw material commodity supply interest rate market value abbvie equity investment performance investment hold employee benefit trust change creditworthiness counterpartie transact business provide service abbvie employee benefit trust environmental liability connection abbvie manufacturing process distribution logistic include handle hazardous material change ability party provide information technology account human resource payroll outsource service abbvie meet contractual obligation abbvie failure perceive failure achieve environmental social governance objective information loss damage abbvie reputation brand image goodwill increase use social medium platform business interruption stem natural disaster climate change earthquake hurricane flooding fire effort take party prevent mitigate disaster change business economic political condition include war political instability terrorist attack threat future terrorist activity relate military action natural disaster cost availability insurance forego event labor dispute strike slow down form labor union activity pressure thirdparty interest group risk relate abbvie common stock abbvie guarantee timing payment dividend common stock repurchase common stock abbvie expect pay regular cash dividend time declaration payment future dividend stockholder fall discretion abbvie board director board decision payment dividend depend factor abbvie financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant information item market registrant common equity relate stockholder matter issuer purchase equity security abbvie ability pay dividend repurchase share share repurchase program depend ongoing ability generate cash operation access capital market abbvie guarantee continue pay dividend future abbvie stockholder percentage ownership abbvie dilute future future stockholder percentage ownership abbvie dilute equity issuance capital market transaction equity awards abbvie grant abbvie director officer employee acquisition purpose abbvie employee option purchase share common stock result conversion abbott stock option abbvie stock option abbvie anticipate compensation committee grant additional stock option stockbase award employee award dilutive effect abbvie earning share adversely affect market price abbvie common stock time time abbvie issue additional option stockbase award employee abbvie employee benefit plan addition abbvie amend restate certificate incorporation authorize abbvie issue approval abbvie stockholder class series prefer stock designation power preference relative participate optional special right include preference abbvie common stock respect dividend distribution abbvie board director generally determine term class series prefer stock dilute voting power reduce value abbvie common stock example abbvie grant holder prefer stock right elect number abbvie director event happen specify event right veto specify transaction similarly repurchase redemption right liquidation preference abbvie assign holder prefer stock affect residual value common stock certain provision abbvie amend restate certificate incorporation amend restate bylaw delaware law prevent delay acquisition abbvie decrease trading price abbvie common stock abbvie amend restate certificate incorporation amend restate bylaw contain delaware law contain provision intend deter coercive takeover practice inadequate takeover bid encourage prospective acquiror negotiate abbvie board director attempt hostile takeover provision include inability abbvie stockholder special meeting division abbvie board director class director class serve stagger threeyear term provision stockholder remove director cause ability abbvie director stockholder fill vacancy abbvie board director requirement affirmative vote stockholder hold abbvie voting stock require amend certain provision abbvie amend restate certificate incorporation abbvie amend restate bylaw relate number term election abbvie director fill board vacancy call special meeting stockholder director officer indemnification provision addition section delaware general corporation law provide subject limited exception person acquire affiliated person acquire outstanding voting stock delaware corporation shall engage business combination corporation include merger consolidation acquisition additional share threeyear period follow date person affiliate holder corporation outstanding voting stock abbvie believe provision protect stockholder coercive unfair takeover tactic require potential acquiror negotiate abbvie board director provide abbvie board director time assess acquisition proposal provision intend company immune takeover provision apply offer consider beneficial stockholder delay prevent acquisition abbvie board director determine good interest abbvie abbvie stockholder provision prevent discourage attempt remove replace incumbent director cautionary statement forwardlooke statement annual report contain certain forwardlooke statement business strategy market potential future financial performance matter word believe expect anticipate project similar expression use future conditional verb generally identify forward look statement speak date statement matter discuss forwardlooke statement subject risk uncertainty factor cause actual result differ materially express imply forwardlooke statement particular information include item business item risk factor item management discussion analysis financial condition result operation contain forward look statement forward look statement expectation belief future result event express imply expectation belief base current plan expectation abbvie management express good faith believe reasonable basis assurance expectation belief result achieve accomplished factor cause actual result event differ materially anticipate include limited matter describe item risk factor item management discussion analysis financial condition result operation abbvie undertake specifically decline obligation update forwardlooke statement include annual report reflect event circumstance date hereof abbvie require applicable security law item b unresolved staff comment item property abbvie corporate office locate north waukegan road north chicago illinois december abbvie own lease approximately facility worldwide contain aggregate approximately million square foot floor space dedicate production distribution administration abbvie significant manufacturing facility follow location united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico clonshaugh ireland branchburg new jersey la aurora costa rica campbell california ludwigshafen germany cincinnati ohio pringy france dublin california singapore irvine california sligo ireland north chicago illinois westport ireland waco texas worcester massachusetts wyandotte michigan lease property abbvie believe facility suitable provide adequate production capacity current project operation material encumbrance abbvie own property unite states include puerto rico abbvie central distribution center abbvie research development facilities united states locate abbott park illinois branchburg new jersey cambridge massachusetts irvine california madison new jersey north chicago illinois pleasanton california santa cruz california south san francisco california worcester massachusetts outside united states abbvie principal research development facility locate ludwigshafen germany form kitem legal proceeding information pertain legal proceeding provide note legal proceeding contingency consolidated financial statement include item financial statement supplementary datum incorporate reference item safety disclosure applicable information executive officer follow table list abbvie executive officer age position richard gonzalez chairman board chief executive officer robert michael vice chairman president scott reents executive vice president chief financial officer timothy j richmond executive vice president chief human resource officer azita salekigerhardt phd executive vice president operation perry c siatis executive vice president general counsel secretary jeffrey r stewart executive vice president chief commercial officer thomas j hudson md senior vice president research development chief scientific officer elaine k sorg senior vice president abbvie president commercial operation carrie strom senior vice president abbvie president global allergan aesthetics brian l durkin vice president controller mr gonzalez chairman chief executive officer abbvie serve abbotts executive vice president pharmaceutical product group july december responsible abbotts worldwide pharmaceutical business include commercial operation research development manufacturing serve president abbott ventures inc abbotts medical technology investment arm mr gonzalez join abbott hold management position appoint abbvie corporate officer december mr michael abbvies vice chairman president mr michael previously serve vice chairman finance commercial operation chief financial officer june june executive vice president chief financial officer senior vice president chief financial officer vice president controller serve abbvie vice president treasurer vice president controller commercial operation vice president financial planning analysis abbott mr michael serve division controller nutrition supply chain mr michael join abbott appoint abbvie corporate officer march mr reents abbvies executive vice president chief financial officer previously serve senior vice president chief financial officer june november vice president tax treasury june vice president tax mr reent join abbott appoint abbvie corporate officer june mr richmond abbvies executive vice president chief human resource officer serve senior vice president human resources mr richmond serve abbotts divisional vice president compensation benefit group vice president talent reward divisional vice president talent acquisition mr richmond join abbott appoint abbvie corporate officer december dr salekigerhardt abbvie executive vice president operation serve senior vice president operation dr salekigerhardt serve abbotts vice president pharmaceutical manufacturing supply divisional vice president quality assurance global pharmaceutical operation dr salekigerhardt join abbott appoint abbvie corporate officer december serve board entegris inc mr siatis abbvie executive vice president general counsel secretary mr siatis previously serve senior vice president deputy general counsel september october mr siatis serve role include senior vice president legal chief ethic compliance officer senior vice president legal transaction rdalliance management chief ethic compliance officer vice president biologic strategic development legal regulatory mr siatis join abbott appoint abbvie corporate officer october mr stewart abbvie executive vice president chief commercial officer previously serve senior vice president commercial operation abbvie president commercial operation form k prior abbvie separation abbott serve vice president abbott proprietary pharmaceutical division united states mr stewart join abbott appoint abbvie corporate officer december dr hudson abbvie senior vice president research development chief scientific officer previously serve vice president head oncology discovery early development prior join abbvie dr hudson serve ontario institute cancer research president scientific director previously serve founder director mcgill university genome quebec innovation centre assistant director whiteheadmit center genome research dr hudson appoint abbvie corporate officer july ms sorg abbvie senior vice president abbvie president commercial operation previously serve abbvie president immunology patient service vice president immunology oncology serve vice president immunology prior abbvie separation abbott abbvie ms sorg join abbott appoint abbvie corporate officer november prior join abbott ms sorg serve management role eli lilly company year ms strom abbvie senior vice president abbvie president global allergan aesthetics responsible worldwide operation aesthetic franchise appoint position abbvie acquisition allergan appoint abbvie corporate officer allergan ms strom previously serve senior vice president medical aesthetic join allergan mr durkin abbvie vice president controller mr durkin previously serve vice president internal audit prior join abbvie serve vice president finance division controller abbotts vision care business controller pharmaceutical research development mr durkin join abbott appoint abbvie corporate officer october executive officers abbvie elect annually board director officer elect board appoint chairman board officer elect meeting board director hold annual stockholder meeting appoint chairman board board meeting officer hold office successor duly elect appoint qualified officer death resignation removal family relationship executive officer list ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market principal market abbvie common stock new york stock exchange symbol abbv abbvie common stock list chicago stock exchange trade regional electronic exchange stockholder stockholder record abbvie common stock january performance graph follow graph compare cumulative total return abbvie sp index nyse arca pharmaceuticals index period december december graph assume invest abbvie common stock index december assume reinvestment dividend stock price performance follow graph necessarily indicative future stock price performance performance graph furnish shall deem file sec subject section security exchange act shall deem incorporate reference abbvie filing securities act amend form kdividend october abbvie board director declare increase quarterly cash dividend share share payable february stockholders record january time declaration payment dividend abbvie future discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director abbvie determine pay dividend future assurance continue pay dividend dividend issuer purchase equity security total number share unit total purchase maximum number number average publicly approximate dollar value share price announce share unit unit pay share plan purchase period purchase unit program plan programs october october november november december december total addition abbvie share repurchase open market publicly announce program share include share purchase open market benefit participant abbvie employee stock purchase plan october november december share include share surrender abbvie satisfy minimum tax withholding obligation connection vest exercise stockbase award item reserve form kitem management discussion analysis financial condition result operation follow discussion analysis financial condition abbvie inc abbvie company commentary read conjunction consolidated financial statement accompany note appear item financial statement supplementary datum section generally discuss item yeartoyear comparison discussion item yeartoyear comparison include find management discussion analysis financial condition result operation ii item company annual report fiscal year end december executive overview company overview abbvie global diversify researchbase biopharmaceutical company position success comprehensive product portfolio leadership position immunology oncology aesthetic neuroscience eye care abbvie use expertise dedicated people unique approach innovation develop market advanced therapy address world complex disease abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse certain product include aesthetic product device sell directly physician license healthcare providers united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly retailer pharmacy patient customer outside united states abbvie sell product primarily wholesaler distributor depend market work largely centralized national payer system agree reimbursement term certain product comarkete copromote company abbvie operate single global business segment approximately employee financial result abbvie strategy focus deliver strong financial result maximize benefit allergan acquisition advance invest pipeline return value shareholder ensure strong sustainable growth business long term company financial performance include deliver worldwide net revenue billion operating earning billion dilute earning share cash flow operation billion worldwide net revenue increase report basis constant currency basis reflect growth immunology neuroscience aesthetic portfolio dilute earning share include follow aftertax cost billion relate amortization intangible assets ii billion change fair value contingent consideration liability iii billion charge relate litigation matter iv million acquisition integration expense v million relate intangible asset impairment cost partially offset aftertax gain million relate divestiture pylera benefit million relate certain tax item additionally financial result reflect continued funding support stage abbvie pipeline asset continue investment abbvie onmarket brand follow close allergan acquisition abbvie implement integration plan design reduce cost integrate optimize combine organization result successful execution integration plan abbvie realize billion annual cost synergy achieve integration objective abbvie incur total cumulative charge billion cost consist severance employee benefit cost cash severance noncash severance include accelerated equity award compensation expense retention termination benefit integration expense recent global event russiaukraine response military conflict russia ukraine united states north atlantic treaty organization member state certain nonmember state announce target economic sanction export control russia belarus include restriction export transfer product contain certain toxin include botox russia belarus abbvie prohibit continue sale essential pharmaceutical product help ensure patient receive uninterrupted supply medicine march abbvie announce suspension operation aesthetic product russia april abbvie announce profit sale essential medicine russia donate support direct humanitarian relief effort ukraine company operation russia belarus ukraine significant conflict escalate result broad economic political concern abbvie business adversely impact impact coronavirus disease covid response covid abbvie continues closely manage manufacture supply chain resource world help ensure patient continue receive uninterrupted supply medicine clinical trial site monitor locally protect safety study participant staff employee impact covid abbvie operation date material abbvie continue experience low new patient start certain product market abbvie expect matter continue negatively impact result operation duration pandemic extent covid impact abbvie financial condition result operation remain uncertain dependent numerous evolve factor include measure take authority mitigate spread covid emergence new variant effectiveness vaccine therapeutic strategic objective abbvie mission discover develop innovative medicine product solve health issue today address medical challenge tomorrow achieve topti financial performance outstanding execution abbvie intends execute strategy advance mission number way include maximize benefit diversify revenue base multiple longterm growth driver ii leverage abbvie commercial strength international infrastructure therapeutic area ensure strong commercial execution new product launch iii continue invest expand pipeline support opportunity immunology oncology aesthetic neuroscience eye care continue investment key market product iv generate substantial operating cash flow support investment innovative research development return cash shareholder strong grow dividend reduce debt addition abbvie anticipate regulatory submission datum readout key clinical trial month abbvie expect achieve strategic objective skyrizi rinvoq revenue growth drive increase market share indication expansion advance hematologic oncology portfolio increase venclexta market share new indication strong commercial execution new product launch effectively manage market competitive challenge impact imbruvica continue investment global expansion aesthetic increase market penetration botox juvederm collection neuroscience revenue growth drive vraylar botox therapeutic ubrelvy qulipta maximize abbvie exist eye care portfolio effectively manage impact humira biosimilar erosion favorable impact pipeline product indication recently approve currently regulatory review approval expect product describe great detail section label research development include item form kresearch development research innovation cornerstone abbvie business global biopharmaceutical company abbvie longterm success depend great extent ability continue discover develop innovative product acquire collaborate compound currently development biotechnology pharmaceutical company abbvie pipeline currently include compound device indication development individually collaboration license agreement focus important specialty immunology oncology aesthetic neuroscience eye care program approximately mid latestage development follow section summarize transition significant program midstage development latestage development development significant latestage registration program abbvie expect multiple midstage program transition latestage program month significant program development immunology skyrizi january abbvie announce food drug administration fda approve skyrizi treatment adult active psoriatic arthritis june abbvie announce fda approve skyrizi treatment adult moderately severely active crohns disease november abbvie announce european commission ec approve skyrizi treatment adult moderately severely active crohn disease inadequate response lose response intolerant conventional biologic therapy rinvoq january abbvie announce fda approve rinvoq treatment moderate severe atopic dermatitis adult child year age old disease respond previous treatment control pill injection include biologic medicine use pill injection recommend february abbvie announce topline result second phase induction study uexcel rinvoq patient moderate severe crohns disease inadequate response intolerant conventional biologic therapy meet primary key secondary endpoint march abbvie announce fda approve rinvoq treatment adult moderately severely active ulcerative colitis uc inadequate response intolerance tumor necrosis factor tnf blocker april abbvie announce fda approve rinvoq treatment adult active ankylose spondylitis inadequate response intolerance tnf blocker abbvie announce positive topline result uendure phase maintenance study rinvoq adult patient moderate severe crohn disease inadequate response intolerant conventional biologic therapy result show patient treat rinvoq achieve coprimary secondary endpoint year compare placebo july abbvie announce ec approve rinvoq treatment adult moderately severely active uc inadequate response lose response intolerant conventional therapy biologic agent july abbvie announce submission supplemental new drug application snda fda marketing authorization application maa ema rinvoq treatment adult patient moderately severely active crohns disease july abbvie announce ec approve rinvoq treatment adult patient active nonradiographic axial spondyloarthritis nraxspa october abbvie announce fda approve rinvoq treatment adult active nraxspa objective sign inflammation inadequate response intolerance tnf blocker therapy november abbvie announce ema committee medical product human use chmp adopt opinion follow review benefitrisk medicine jak inhibitor class treatment inflammatory disease include rinvoq confirm recommendation pharmacovigilance risk assessment committee prac chmp recommend change current rinvoq indication statement recommend update dosage special warning jak inhibitor product indicate treatment inflammatory disease recommendation forward ec expect issue final decision oncology telisov january abbvie announce fda grant breakthrough therapy designation investigational telisotuzumab vedotin telisov treatment patient advancedmetastatic epidermal growth factor receptor wild type nonsquamous nonsmall cell lung cancer high level cmet overexpression disease progress platinumbase therapy abbvie initiate phase clinical trial evaluate telisov versus docetaxel treatment patient previously treat cmet overexpresse epidermal growth factor receptor wild type advancedmetastatic nonsquamous nonsmall cell lung cancer epcoritamab march genmab genmab announce fda grant orphandrug designation investigational medicine epcoritamab duobodycdxcd treatment follicular lymphoma genmab abbvie codevelope epcoritamab share commercial responsibility japan abbvie responsible global commercialization june abbvie genmab announce primary result large bcell lymphoma expansion cohort epcore nhl phase clinical trial evaluate epcoritamab investigational subcutaneous bispecific antibody study epcoritamab demonstrate efficacy durable response patient previously receive prior line antilymphoma therapy include chimeric antigen receptor tcell therapy september abbvie genmab submit biological license application bla fda epcoritamab treatment patient relapsedrefractory large bcell lymphoma october abbvie genmab submit maa ema epcoritamab treatment patient relapsedrefractory diffuse large bcell lymphoma october abbvie initiate phase clinical trial evaluate epcoritamab combination rituximab lenalidomide compare rituximab lenalidomide patient relapse refractory follicular lymphoma november abbvie announce fda accept priority review bla epcoritamab treatment relapsedrefractory large bcell lymphoma imbruvica august abbvie announce fda approve use imbruvica treatment pediatric patient year old chronic graft versus host disease failure line systemic therapy august national comprehensive cancer network nccn united states issue update guideline management chronic lymphocytic leukemia cll recategorize imbruvica prefer regimen recommend regimen form kaesthetic juvederm collection february abbvie announce fda approve juvederm volbella xc improvement infraorbital hollow adult age august abbvie announce fda approve juvederm volux xc improvement jawline definition adult age moderate severe loss jawline definition bonte march abbvie initiate phase clinical trial evaluate efficacy safety bonte agn treatment glabellar line neuroscience vraylar december abbvie announce fda approve vraylar adjunctive therapy antidepressant treatment major depressive disorder adult qulipta march abbvie announce result phase progress trial qulipta preventive treatment chronic migraine adult meet primary endpoint result significant improvement secondary endpoint adjustment multiple comparison june abbvie submit snda fda qulipta preventative treatment chronic migraine adult july abbvie submit maa ema qulipta prophylactic treatment migraine adult patient migraine day month abbv abbvie submit new drug application fda abbv foscarbidopafoslevodopa treatment motor fluctuation patient advance parkinson disease result operation net revenue comparison present constant currency rate reflect comparative local currency net revenue prior year foreign exchange rate measure provide information change net revenue assume foreign currency exchange rate change prior current period abbvie believe nongaap measure change net revenue constant currency rate conjunction gaap measure change net revenue actual currency rate provide complete understand company operation facilitate analysis company result operation particularly evaluate performance period percent change actual currency rate constant currency rate year end dollar millions united states international net revenue form kthe follow table detail abbvie worldwide net revenue percent change actual currency rate constant currency rate year end december dollar million immunology humira united states international total skyrizi united states international total rinvoq united states international total hematologic oncology imbruvica united states collaboration revenue total venclexta united states international total aesthetic botox cosmetic united states international total juvederm collection united states international total aesthetics united states international total neuroscience botox therapeutic united states international total vraylar united states international nm nm nm nm total duodopa united states international total ubrelvy united states qulipta united states nm nm neuroscience united states international total percent change actual currency rate constant currency rate year end december dollar millions eye care lumiganganfort united states international total alphagancombigan united states international total restasis united states international total eye care united states international total key product mavyret united states international total creon united states linzessconstella united states international total total net revenue nm meaningful net revenue include allergan product revenue acquisition closing date follow discussion analysis abbvie net revenue product present constant currency basis global humira sale increase primarily drive market growth therapeutic category partially offset direct biosimilar competition international market united states humira sale increase primarily drive market growth indication favorable pricing increase partially offset low market share follow correspond market share gain skyrizi rinvoq internationally humira revenue decrease primarily drive direct biosimilar competition january humira lose exclusivity united states follow loss exclusivity abbvie expect direct biosimilar competition humira net revenues decline united states abbvie continue pursue strategy maintain broad formulary access humira manage impact biosimilar erosion net revenue skyrizi increase primarily drive continued strong volume market share uptake launch treatment plaque psoriasis market growth net revenue favorably impact recent regulatory approval expansion skyrizi treatment psoriatic arthritis crohns disease net revenue rinvoq increase primarily drive continued strong volume market share uptake launch treatment moderate severe rheumatoid arthritis market growth net revenue favorably impact recent regulatory approval expansion rinvoq treatment psoriatic arthritis atopic dermatitis ankylose spondylitis ulcerative colitis nonradiographic axial spondyloarthritis net revenues imbruvica represent product revenues united states collaboration revenue outside united states relate abbvie share imbruvica profit abbvie global imbruvica revenue decrease result decrease market demand low market share united states decrease net revenue partially offset increase collaboration revenue net revenues venclexta increase primarily continued expansion venclexta treatment patient cll acute myeloid leukemia form knet revenue botox cosmetic increase sustained consumer demand united states moderate second half year economic pressure impact consumer discretionary spending increase investment key international market net revenue juvederm collection decrease economic pressure impact consumer discretionary spending increase pricing promotion support market international net revenue increase increase investment key market partially offset suspension aesthetic operation russia impact covid china net revenue botox therapeutic increase market growth net revenue vraylar increase high market share market growth net revenue ubrelvy increase primarily increase market share uptake launch partially offset unfavorable pricing net revenue qulipta increase great strong volume market share uptake launch preventative treatment episodic migraine adult net revenue mavyret decrease continued disruption global hepatitis c virus market covid pandemic gross margin percent change year end december dollar million gross margin percent net revenue gross margin percentage net revenue increase compare gross margin percentage favorably impact change product mix partially offset intangible asset impairment charge million sell general administrative percent change year end december dollar million sell general administrative percent net revenue sell general administrative sga expense percentage net revenue increase compare prior year primarily unfavorable impact litigation reserve charge billion partially offset leverage revenue growth increase synergy realize research development acquire iprd milestone percent change year end december dollar million research development percent net revenue acquire iprd milestone rd expense percentage net revenue decrease compare rd expense percentage favorably impact increase scale combine company synergy realize purchase priority review voucher party prior year low integration cost relate acquisition allergan acquire iprd milestone expense represent upfront subsequent development milestone payment incur prior regulatory approval acquire right inprocess rd project rd collaboration license arrangement asset acquisition acquire iprd milestone expense include charge million relate acquire syndesi therapeutic sa charge related upfront payment total million development milestone million acquire iprd milestone expense include charge million relate exercise company exclusive right acquire teneoone charge million relate collaboration agreement regenxbio inc charge related upfront payment total million development milestone million note consolidated financial statement additional information operate expense net operating expense net include onetime charge million related asset divest allergan acquisition partially offset million income relate sale worldwide commercial right mature brand pylera operating expense net include million charge relate extension calico life sciences llc collaboration note consolidated financial statement additional information nonoperating expense year end december million interest expense interest income interest expense net net foreign exchange loss expense net interest expense decrease compare primarily low average debt balance result deleverage partially offset impact high interest rate interest income increase compare primarily impact high interest rate expense net include charge relate change fair value contingent consideration liabilitie billion billion fair value contingent consideration liability impact passage time multiple input include probability success achieve regulatorycommercial milestone discount rate estimate future sale acquire product marketbase factor change fair value reflect higher estimate skyrizi sale drive strong market share uptake passage time partially offset high discount rate change fair value reflect higher estimate skyrizi sale drive strong market share uptake favorable clinical trial result passage time partially offset high discount rate income tax expense effective income tax rate negative effective income tax rate differ statutory tax rate principally impact foreign operation reflect impact low income tax rate location outside united states tax incentive puerto rico foreign tax jurisdiction business development activity change fair value contingent consideration effective tax rate period reflect benefit tax credit principally relate research development credit orphan drug tax credit puerto rico excise tax credit puerto rico tax credit relate excise tax certain product manufacture puerto rico tax levy gross inventory purchase entities puerto rico include cost product sell consolidated statement earning majority tax creditable income tax purpose puerto rico enact act puerto rico act allow transition puerto rico excise tax levy gross inventory purchase incomebase tax begin company complete transition requirement puerto rico act result remeasurement certain defer tax asset liability base income tax rate expect reverse future net tax benefit remeasurement defer taxis relate puerto rico act million financial position liquidity capital resource year end december million cash flow provide operating activity invest activity financing activity operate cash flow increase primarily improved result operation result revenue growth low income tax payment partially offset time work capital operating cash flow reflect abbvie contribution define benefit plan million million form kinveste cash flow include payment capital expenditure million acquisition investment million million cash consideration pay acquire djs antibodies ltd offset cash acquire net sale maturity investment security total million investment cash flow include million cash consideration pay acquire soliton inc offset cash acquire payment acquisition investment billion capital expenditure million net purchase investment security total million financing cash flow include repayment billion aggregate principal company senior note billion aggregate principal company senior note billion aggregate principal company senior note billion aggregate principal company senior note billion aggregate principal company senior note million aggregate principal company float rate senior note additionally finance cash flow include repayment billion float term loan issuance new billion float rate term loan term loan refinancing february subsequent december company repay billion float rate threeyear term loan schedule mature finance cash flow include early repayment billion aggregate principal company principal note billion aggregate principal company senior note million aggregate principal company senior euro note finance cash flow include repayment million aggregate principal float rate senior note billion aggregate principal senior note billion aggregate principal senior note million aggregate principal float rate senior note maturity additionally finance cash flow include repayment billion float rate term loan issuance new billion float rate term loan term loan refinance september financing cash flow include cash dividend payment billion billion increase cash dividend payment primarily drive increase dividend rate company stock repurchase authorization permit purchase abbvie share time time openmarket private transaction management discretion program time limit discontinue time abbvie repurchase million share billion million share million abbvie remain stock repurchase authorization billion december february abbvie board director authorize billion increase exist stock repurchase authorization commercial paper borrowing issue commercial paper borrowing outstanding december december abbvie issue additional commercial paper retire commercial paper meet liquidity requirement need credit risk abbvie monitor economic condition creditworthiness customer government regulation fund domestically abroad abbvie regularly communicate customer status receivable balance include payment plan obtain positive confirmation validity receivables abbvie establishe allowance credit loss equal estimate future loss contractual life outstanding account receivable abbvie utilize factoring arrangement mitigate credit risk receivable include arrangement historically significant total outstanding receivables credit facility access capital credit rating credit facility abbvie currently billion fiveyear revolve credit facility mature august credit facility enable company borrow fund unsecured basis variable interest rate contain covenant december company compliance covenant commitment fee credit facility insignificant amount outstanding company credit facility december december access capital company intend fund shortterm longterm financial obligation mature cash hand future cash flow operation ability issue additional debt company ability generate cash flow operation issue debt enter financing arrangement acceptable term adversely affect material decline demand company product solvency customer supplier deterioration company key financial ratio credit rating material unfavorable change business condition current time company believe sufficient financial flexibility issue debt enter financing arrangement attract longterm capital acceptable term support company growth objective credit rating moodys investor service upgrade abbvie senior unsecured longterm credit rating baa baa affirm prime shortterm credit rating revise outlook positive stable addition standard poor global rating revise outlook positive stable affirmed longterm issuer credit rating bbb unfavorable change rating adverse impact future financing arrangement affect company ability draw credit facility result acceleration schedule maturity company outstanding debt future cash requirement contractual obligation follow table summarize abbvie estimate material contractual obligation december million total current longterm longterm debt include current portion interest longterm debta contingent consideration liabilitiesb include estimate future interest payment longterm debt interest payment debt calculate future period forecast interest rate effect end project interest payment include relate effect interest rate swap agreement certain project interest payment differ future base change float interest rate factor event project interest payment pertain obligation agreement outstanding december note consolidated financial statement additional information company debt instrument note additional information interest rate swap agreement outstanding december b include contingent consideration liability record fair value consolidate balance sheet potential contingent consideration payment exceed fair value record consolidated balance sheet include table contractual obligation note consolidated financial statement additional information liability abbvie enter certain unconditional purchase obligation commitment normal course business change commitment material impact company ability meet shortterm longterm future cash requirement income taxis future income tax cash requirement include onetime transition tax liability mandatory deem repatriation previously untaxe earning foreign subsidiary result tax reform enact onetime transition tax liability billion december payable future annual installment liability unrecognize tax benefit total billion december possible reliably estimate time future cash outflow relate liability note consolidated financial statement additional information unrecognized tax benefit quarterly cash dividend october abbvie announce board director declare increase quarterly cash dividend share share beginning dividend payable february stockholders record january reflects increase approximately previous quarterly rate timing form kdeclaration payment dividend abbvie future discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director collaboration license arrangement abbvie enter collaborative licensing arrangement party require future milestone payment party contingent achievement certain development regulatory commercial milestone individually arrangement insignificant annual reporting period milestone multiple product cover arrangement happen reach reporting period aggregate charge expense material result operation period business perspective payment view positive signify product successfully move development generating likely generate future cash flow product sale possible predict reasonable certainty milestone achieve timing achievement note consolidated financial statement additional information collaboration arrangement critical accounting policy estimate preparation financial statement accordance generally accept accounting principle united states require use estimate assumption affect report amount asset liability report amount revenue expense summary company significant accounting policy include note consolidated financial statement certain policy consider critical significantly impact company financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain actual result vary estimate revenue recognition abbvie recognize revenue control promise good service transfer company customer reflect consideration abbvie expect entitled exchange good service sale value add taxis collect concurrent revenue produce activity exclude revenue abbvie generate revenue primarily product sale majority sale company transfer control invoice customer recognize revenue shipment customer rebate abbvie provide rebate pharmacy benefit manager state government medicaid programs insurance company administer medicare drug plan wholesaler group purchasing organization government agency private entity rebate chargeback accrual account variable consideration record reduction revenue period relate product sell provision rebate chargeback total billion billion billion rebate amount typically base volume purchase contractual statutory price vary product payer type rebate factor calculation accrual rebate include identification product subject rebate applicable price term estimate lag time sale payment rebate significant order establish rebate chargeback accruals company use internal external datum estimate level inventory distribution channel rebate claim processing lag time type rebate estimate rebate percentage net price company track sale product customer payer company evaluate inventory datum report wholesaler available prescription volume information product pricing historical experience factor order determine adequacy reserve abbvie regularly monitor reserve record adjustment rebate trend rebate program contract term legislative change significant event indicate change reserve appropriate historically adjustment rebate accrual material net earning follow table analysis large accrual rebate chargeback comprise approximately total consolidated rebate chargeback record reduction revenue remain rebate provision charge gross revenue significant determination operating earning medicaid manage medicare care wholesaler millions rebate rebate chargeback balance december additionsa provision payment balance december provision payment balance december provision payment balance december represent rebate accrual chargeback allowance assume allergan acquisition allowance allowance include cash discount product return sale incentive adjustment account variable consideration record reduction revenue period relate product sell reserve cash discount sale incentive readily determinable company experience payment history fairly consistent product return reliably estimate base company historical return experience cash discount total billion billion billion allowance cash discount significant pension postemployment benefit abbvie engage outside actuary assist determination obligation cost pension postemployment benefit plan direct obligation abbvie valuation fund status net periodic benefit cost plan calculate actuarial assumption significant assumption review annually include discount rate expect longterm rate return plan asset health care cost trend rate disclose note consolidated financial statement discount rate select base current market rate highquality fixedincome investment december year abbvie employs yield curve approach country robust bond market exist yield curve develop highquality bond yieldcurve approach reflect plan specific cash flow ie duration calculate benefit obligation apply correspond individual spot rate yield curve abbvie reflect plan specific cash flow apply correspond individual spot rate yield curve calculate service cost interest cost portion expense country abbvie review index corporate bond government bond benchmark estimate discount rate form kabbvie assume discount rate significant effect amount report define benefit pension postemployment plan december basis point change assume discount rate follow effect abbvie calculation net periodic benefit cost project benefit obligation december basis point million bracket denote reduction increase decrease define benefit plan net periodic benefit cost project benefit obligation postemployment plan net periodic benefit cost project benefit obligation expect longterm rate return base asset allocation historical performance current view expect future return abbvie consider input longterm focus avoid shortterm market influence current longterm rate return plan asset plan support historical performance trust actual target asset allocation abbvie assume expected longterm rate return significant effect amount report define benefit pension plan december calculation net periodic benefit cost percentage point change assume expected longterm rate return plan asset increase decrease net period benefit cost plan million health care cost trend rate select review historical trend current view project future health care cost increase current health care cost trend rate support historical trend experience plan assume health care cost trend rate significant effect amount report health care plan december calculation net periodic benefit cost income taxis abbvie account income taxis asset liability method provision federal state foreign income taxis calculate report pre tax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize litigation company subject contingency claim legal proceeding investigation product liability intellectual property commercial security matter arise normal course business note consolidated financial statement additional information loss contingency provision record probable loss management good estimate loss good estimate minimum loss contingency probable range record accordingly abbvie initially unable develop good estimate loss minimum zero record information know minimum loss increase result additional loss provision good estimate result additional loss provision occasionally good estimate change low event result expectation favorable outcome previously expect valuation goodwill intangible asset abbvie acquire continue acquire significant intangible asset connection business combination abbvie record fair value transaction involve purchase sale intangible asset occur company pharmaceutical industry valuation usually base discount cash flow analysis incorporate stage completion discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant factor significantly affect value intangible asset process research development iprd acquire business combination capitalize indefinitelive intangible asset regulatory approval obtain time account definitelived asset amortize estimate useful life discontinuation point intangible asset write iprd acquire transaction business combination expense immediately deem alternative future use payment party subsequent regulatory approval capitalize amortize remain useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable goodwill indefinitelive intangible asset review impairment annually event occur result impairment note consolidated financial statement additional information annually company test goodwill impairment assess qualitative factor determine likely fair value carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor overall financial performance sustained decline company share price company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset impairment assess qualitative factor determine likely fair value carrying company conclude likely fair value carrying quantitative impairment test perform quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view use alternative estimate assumption increase decrease project cash flow estimate fair value relate intangible asset future change estimate assumption material impact company result operation actual result differ company estimate contingent consideration fair value measurement contingent consideration liability determine acquisition date base significant unobservable input include discount rate estimate probability time achieve specify development regulatory commercial milestone estimate future sale acquire product contingent consideration liability revalue fair value subsequent reporting date relate contingency resolve potential contingent consideration payment estimate apply probabilityweighte expect payment model contingent milestone payment monte carlo simulation model contingent royalty payment discount present value change fair value contingent consideration liability result change number input include discount rate probability achieve milestone time require achieve milestone estimate future sale significant judgment employ determine appropriateness certain input disclose note consolidated financial statement change input describe material impact company financial position result operation give period form kitem quantitative qualitative disclosure market risk company expose risk earning cash flow equity adversely impact change foreign exchange rate interest rate certain derivative instrument available costeffective basis hedge company underlie economic exposure note consolidated financial statement additional information company financial instrument hedge strategy foreign currency risk abbvie primary net foreign currency exposure euro japanese yen canadian dollar chinese yuan british pound follow table reflect total foreign currency forward exchange contract outstanding december weight fair weight fair average exchange carry value average exchange carrying value december million contract rate receivablepayable contract rate receivablepayable receive primarily dollar exchange follow currency euro canadian dollar british pound chinese yuan japanese yen currency na na total company estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract billion december realize appreciation negatively affect earning remain life contract gain loss hedge instrument offset loss gain hedge transaction reduce earning stockholder equity volatility relate foreign exchange appreciation believe reasonably possible nearterm change foreign currency december company billion aggregate principal unsecured senior euro note outstanding expose foreign currency risk company designate foreign currency denominate note hedge net investment certain foreign subsidiary affiliate result foreign currency translation gain loss relate euro note include accumulate comprehensive loss note consolidated financial statement additional information senior euro note note consolidated financial statement additional information net investment hedging program interest rate risk company estimate increase interest rate basis point adversely impact fair value abbvie interest rate swap contract approximately million december realize fair value reduction affect earning remain life contract company estimate increase basis point longterm interest rate decrease fair value longterm debt billion december basis point change believe reasonably possible nearterm change interest rate item financial statement supplementary datum consolidate financial statement consolidate statement earning consolidate statement comprehensive income consolidate balance sheet consolidate statement equity consolidate statement cash flow note consolidated financial statement note background note summary significant accounting policy note supplemental financial information note earning share note license acquisition arrangement note collaboration note goodwill intangible asset note integration restructuring plan note lease note debit credit facility commitment contingency note financial instrument fair value measure note postemployment benefit note equity note income taxis note legal proceeding contingency note segment geographic area information note fourth quarter financial result unaudite report independent register public accounting firm pcaob d form kabbvie inc subsidiary consolidate statement earning year end december millions share datum net revenue cost product sell sell general administrative research development acquire iprd milestone operating expense net total operating cost expense operate earning interest expense net net foreign exchange loss expense net earning income tax expense income tax expense benefit net earning net earning attributable noncontrolle interest net earning attributable abbvie inc share datum basic earning share attributable abbvie inc dilute earning share attributable abbvie inc weightedaverage basic share outstanding weightedaverage dilute share outstanding accompany note integral consolidated financial statement abbvie inc subsidiary consolidate statement comprehensive income year end december million net earning foreign currency translation adjustment net tax expense benefit net investment hedging activity net tax expense benefit pension postemployment benefit net tax expense benefit cash flow hedging activity net tax expense benefit comprehensive income comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable abbvie inc accompany note integral consolidated financial statement form kabbvie inc subsidiary consolidate balance sheet december millions share datum asset current asset cash equivalent shortterm investment account receivable net inventory prepaid expense total current asset investment property equipment net intangible asset net goodwill asset total asset liabilitie equity current liability shortterm borrowing current portion longterm debt finance lease obligation account payable accrue liability total current liability longterm debt finance lease obligation defer income taxis longterm liability commitment contingency stockholder equity common stock par value share authorize share issue december december common stock hold treasury cost share december december additional paidin capital retain earning accumulate comprehensive loss total stockholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement abbvie inc subsidiary consolidate statement equity common share common treasury additional retain accumulate noncontrolle year end december million outstanding stock stock paidin capital earning comprehensive loss interest total balance december net earning attributable abbvie inc comprehensive income net tax dividend declare common share equity award issue acquisition allergan plc purchase treasury stock stockbase compensation plan change noncontrolle interest balance december net earning attributable abbvie inc comprehensive income net tax dividend declare purchase treasury stock stockbase compensation plan change noncontrolle interest balance december net earning attributable abbvie inc comprehensive income net tax dividend declare purchase treasury stock stockbase compensation plan change noncontrolle interest balance december accompanying note integral consolidated financial statement form kabbvie inc subsidiary consolidate statement cash flow year end december million bracket denote cash outflow cash flow operating activity net earning adjustment reconcile net earning net cash operating activity depreciation amortization intangible asset defer income taxis change fair value contingent consideration liability stockbase compensation acquire iprd milestone charge relate collaboration gain divestiture noncash litigation reserve adjustment net cash payment impairment intangible asset net change operate asset liability net acquisition account receivable inventory prepaid expense asset account payable liability income tax asset liability net cash flow operating activity cash flow invest activity acquisition business net cash acquire acquisition investment acquisition property equipment purchase investment security sale maturity investment security net cash flow invest activity cash flow financing activity proceed issuance longterm debt repayment longterm debt finance lease obligation debt issuance cost dividend pay purchase treasury stock proceed exercise stock option payment contingent consideration liability net cash flow financing activity effect exchange rate change cash equivalent net change cash equivalent cash equivalent begin year cash equivalent end year supplemental information interest pay net portion capitalize income taxis pay supplemental schedule noncash investing financing activity issuance common share associate acquisition business accompany note integral consolidated financial statement abbvie inc subsidiary note consolidated financial statement note background background principal business abbvie inc abbvie company discovery development manufacturing sale broad line therapy address world complex disease abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse certain product include aesthetic product device sell directly physician license healthcare providers united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly retailer pharmacy patient customer outside united states abbvie sell product primarily wholesaler distributor depend market work largely centralized national payer system agree reimbursement term abbvie incorporate delaware april january abbvie independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott shareholder abbvie complete acquisition allergan plc allergan refer note additional information acquisition note summary significant accounting policy use estimate consolidated financial statement prepare accordance generally accept accounting principle gaap necessarily include amount base estimate assumption management actual result differ amount significant estimate include amount rebate pension postemployment benefit income taxis litigation valuation goodwill intangible asset contingent consideration liability financial instrument inventory account receivable exposure basis consolidation consolidated financial statement include account abbvie subsidiary control interest maintain control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity abbvie determine primary beneficiary investment company abbvie significant influence control interest account equity method abbvie share earning loss report expense net consolidated statement earning intercompany balance transaction eliminate abbvie revise classification development milestone expense associate licensing collaboration arrangement consolidated statement earning milestone payment incur prior regulatory approval previously include research development rd expense present acquire iprd milestone expense consolidated statement earning reclassification decrease rd expense increase acquire iprd milestone expense million million company believe presentation assist user financial statement well understand total upfront subsequent development milestone payment incur acquire inprocess research development project prior period reclassify conform current period presentation certain reclassification conform prior period consolidated financial statement current period presentation revenue recognition abbvie recognize revenue control promise good service transfer company customer reflect consideration abbvie expect entitled exchange good service sale value add taxis collect concurrent revenue produce activity exclude revenue abbvie generate revenue primarily product sale majority sale company transfer control invoice customer recognize revenue shipment customer company recognize shipping handling cost form kexpense cost product sell company transfer control customer payment term vary depend type location customer base customary commercial term generally year abbvie adjust revenue effect significant financing component contract abbvie expect period transfer good service collection year cash discount rebate chargeback sale incentive product return certain adjustment account variable consideration provision variable consideration base current pricing execute contract government pricing legislation historical datum provide period relate revenue record rebate amount typically base volume purchase contractual statutory price vary product payer type rebate factor calculation accrual include identification product subject rebate applicable price term estimate lag time sale payment rebate significant addition revenue contract customer company recognize certain collaboration revenue note additional information relate collaboration janssen biotech inc genentech inc additionally note disaggregation revenue product geography research development expense internal rd cost expense incur clinical trial cost incur party expense contract work perform acquire iprd milestone expense asset acquisition payment incur prior regulatory approval acquire right inprocess rd project expense acquire iprd milestone expense consolidated statement earning project alternative future use cost include upfront development milestone payment relate rd collaboration license arrangement asset acquisition provide right develop manufacture andor sell pharmaceutical product contingent development milestone payment party prior regulatory approval payment obligation expense milestone result achieve regulatory commercial milestone payment party subsequent regulatory approval capitalize intangible asset amortize cost product sell remain useful life relate product business combination abbvie utilize acquisition method accounting business combination method require thing result operation acquire company include abbvie result operation begin acquisition date asset acquire liability assume recognize fair value acquisition date excess fair value consideration transfer fair value net asset acquire recognize goodwill contingent consideration liability recognize estimate fair value acquisition date subsequent change fair value contingent consideration liability recognize expense net consolidated statement earning fair value asset acquire liability assume certain case subject revision base final determination fair value period time exceed month acquisition date legal cost diligence cost business valuation cost business acquisition cost expense incur business combination fair value iprd project acquire capitalize account indefinitelive intangible asset underlie project receive regulatory approval point intangible asset account definitelive intangible asset discontinuation point intangible asset write rd cost incur company acquisition expense rd incur collaboration arrangement company enter collaborative agreement party develop commercialize drug candidate collaborative activity include joint research development commercialization new product abbvie generally receive certain licensing right arrangement collaboration require upfront payment include additional milestone research development cost share royalty profit share payment contingent occurrence certain future event link success asset development commercialization upfront payment associate collaborative arrangement subsequent payment partner achievement development milestone prior regulatory approval expense acquire iprd milestone expense consolidated statement earning regulatory commercial milestone payment partner subsequent regulatory approval capitalize intangible asset amortize cost product sell estimated useful life relate asset royalty expense cost product sell consolidated statement earning incur advertising cost associate advertising expense incur include sell general administrative sga expense consolidate statement earning advertising expense billion billion billion pension postemployment benefit abbvie record annual expense relate define benefit pension postemployment benefit plan base calculation utilize actuarial assumption include discount rate rate return asset compensation increase turnover rate health care cost trend rate abbvie review actuarial assumption annual basis make modification assumption base current rate trend actuarial gain loss defer accumulate comprehensive income loss aoci net tax amortize remain service attribution period employee corridor method difference expect longterm return plan asset actual annual return generally amortize net periodic benefit cost fiveyear period income taxis income taxis account asset liability method provision federal state foreign income taxis calculate report pre tax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry amount asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize cash equivalent cash equivalent include money market fund time deposit original maturity month investment investment consist primarily equity security heldtomaturity debt security marketable debt security time deposit investment equity security readily determinable fair value record fair value investment equity security readily determinable fair value record cost remeasure fair value base certain observable price change impairment event occur heldtomaturity debt security record cost gain loss investment include expense net consolidated statement earning investment marketable debt security classify availableforsale record fair value unrealize holding gain loss net tax include aoci consolidated balance sheet realize time gain loss recognize earning abbvie periodically assess marketable debt security impairment credit loss decline fair value marketable debt security credit relate factor allowance credit loss record corresponding charge expense net consolidated statement earning abbvie determines noncredit relate impairment occur amortize cost basis investment net allowance credit loss write charge expense net consolidated statement earning availableforsale investment unrealized loss reclassify aoci expense net consolidated statement earning realize gain loss sale investment compute firstin method adjust impairment credit loss record net earning account receivable account receivable state amortize cost allowance credit loss allowance credit loss reflect good estimate future loss contractual life outstanding account receivable determine basis historical experience specific allowance know troubled account currently available information include customer financial condition current forecast economic condition form kinventorie inventory value low cost firstin firstout basis market cost include material conversion cost inventory consist follow december million finish good workinprocess raw material inventory property equipment december million land building equipment construction progress property equipment gross accumulate depreciation property equipment net depreciation property equipment record straightline basis estimate useful life asset estimate useful life building range year building include leasehold improvement amortize less remainder lease term useful life leasehold improvement estimate useful life equipment range year equipment include certain computer software software development cost incur connection develop obtain software internal use amortize year depreciation expense million million million lease shortterm lease term month record balance sheet lease commence modify later abbvie separate lease component nonlease component company record lease liability base present value lease payment lease term abbvie generally use incremental borrowing rate discount lease liability rate implicit lease typically readily determinable certain lease agreement include renewal option company control abbvie include optional renewal period lease term reasonably certain abbvie exercise option variable lease payment include payment lessor taxis maintenance insurance operating cost payment adjust base index rate company lease agreement contain significant residual value guarantee restrictive covenant litigation contingency loss contingency provision record probable liability incur liability reasonably estimate base exist information good estimate minimum loss contingency probable range record legal fee expense incur abbvie accrue product liability claim undiscounte basis liability evaluate quarterly adjust necessary additional information available receivables insurance recovery product liability claim record asset undiscounte basis probable recovery realize goodwill intangible asset intangible asset acquire business combination record fair value discount cash flow model discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant definitelive intangible amortize estimate useful life estimate pattern economic benefit abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable abbvie compare project undiscounted cash flow generate asset carrying value undiscounte cash flow intangible asset carrying value intangible asset write fair value cash flow identify individual asset review apply low level cash flow largely independent cash flow asset liability goodwill indefinitelive asset amortize subject impairment review annually frequently indicator impairment exist impairment goodwill occur carry reporting unit exceed fair value report unit impairment indefinitelive intangible asset occur fair value intangible asset carrying value company test goodwill impairment assess qualitative factor determine likely fair value carrying company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset impairment assess qualitative factor determine likely fair value carrying company conclude likely fair value carrying quantitative impairment test perform quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view use alternative estimate assumption increase decrease project cash flow estimate fair value relate intangible asset future change estimate assumption material impact company result operation actual result differ company estimate foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar periodend exchange rate dollar affect arise translate net asset subsidiary change rate recognize comprehensive income loss consolidate statement comprehensive income net asset subsidiary highly inflationary economy remeasure functional currency report currency remeasurement recognize net foreign exchange loss consolidate statement earning derivative derivative instrument recognize asset liabilitie fair value consolidate balance sheet classify current long term base schedule maturity instrument derivative formally designate hedge company assess inception quarterly hedge derivative highly effective offset change fair value cash flow hedge item change fair value derivative designate fair value hedge hedge item attributable hedge risk recognize earning immediately effective portion change fair value derivative designate cash flow hedge report aoci subsequently recognize earning consistent underlying hedged item determine derivative long highly effective hedge company discontinue hedge accounting prospectively hedge forecast transaction probable occur gain loss reclassify aoci earning derivative designate hedge adjust fair value current earning company use derivative instrument foreign currency denominate debt hedge net investment certain foreign subsidiary affiliate realize unrealized gain loss hedge include aoci derivative cash flow exception net investment hedge principally classified operating section consolidate statement cash flow consistent underlying hedged item cash flow related net investment hedge classify investing section consolidate statement cash flow form knote supplemental financial information interest expense net year end december million interest expense interest income interest expense net account payable accrue liability december million sale rebate dividend payable account payable current portion contingent consideration liability salary wage commission royalty license arrangement account payable accrue liability longterm liability december millions contingent consideration liability liability unrecognize tax benefit income taxis payable pension postemployment benefit longterm liability note earning share abbvie grant certain restrict stock unit rsus consider participate security presence participate security abbvie calculate earning share ep dilutive treasury stock twoclass method period present twoclass method dilutive follow table summarize impact twoclass method year end december millions share datum basic eps net earning attributable abbvie inc earning allocate participate security earning available common shareholder weight average basic share common stock outstanding basic earning share attributable abbvie inc dilute eps net earning attributable abbvie inc earning allocate participate security earning available common shareholder weight average share common stock outstanding effect dilutive security weight average diluted share common stock outstanding diluted earning share attributable abbvie inc certain share issuable stockbase compensation plan exclude computation eps effect antidilutive number common share exclude insignificant period present form knote licensing acquisition arrangement acquisition djs antibodie ltd october abbvie enter agreement acquire djs antibodies ltd djs include lead program djs proprietary heptad platform djs lpar antagonist antibody currently preclinical study treatment idiopathic pulmonary fibrosis fibrotic disease heptad platform potential novel approach antibody discovery specific capability target transmembrane protein target aggregate purchase price million comprise million upfront cash payment million acquisition date fair value contingent consideration liability abbvie owe million future payment achievement certain development milestone transaction account business combination acquisition method accounting acquisition date abbvie acquire million intangible asset inprocess research development million intangible asset develop product right million defer tax liability asset liability assume insignificant acquisition result recognition million goodwill deductible tax purpose acquisition soliton inc december abbvie complete previously announce acquisition soliton inc soliton soliton resonic rapid acoustic pulse device food drug administration fda k clearance longterm improvement appearance cellulite year transaction account business combination acquisition method accounting total consideration transfer allocate purchase price consist cash consideration million pay holder soliton common stock equitybase award warrant transaction date abbvie acquire million intangible asset develop product right assume deferred tax liability total million asset liability insignificant acquisition result recognition million goodwill deductible tax purpose acquisition luminera october abbvie enter agreement luminera privately hold aesthetic company base israel acquire luminera dermal filler portfolio rd pipeline include harmonyca dermal filler intend facial soft tissue augmentation aggregate accounting purchase price million comprise million upfront cash payment million acquisition date fair value contingent consideration liability abbvie owe million future payment achievement certain commercial milestone agreement account business combination acquisition method accounting acquisition date abbvie acquire million intangible asset inprocess research development million intangible asset develop product right asset liability assume insignificant acquisition result recognition million goodwill deductible tax purpose acquisition allergan abbvie complete acquisition outstanding equity interest allergan cash stock transaction allergan global pharmaceutical leader focus develop manufacturing commercialize brand pharmaceutical device biologic surgical regenerative medicine product patient world combination create diverse entity leadership position immunology hematologic oncology aesthetic neuroscience eye care abbvie exist product portfolio pipeline enhance numerous allergan asset allergan product portfolio benefit abbvie commercial strength expertise international infrastructure term acquisition ordinary share allergan common stock convert right receive cash ii share abbvie common stock total consideration acquisition allergan summarize follow million cash consideration pay allergan shareholder fair value abbvie common stock issue allergan shareholder b fair value abbvie equity award issue allergan equity award holder c total consideration represent cash consideration transfer outstanding allergan ordinary share base million allergan ordinary share outstanding closing b represent acquisition date fair value million share abbvie common stock issue allergan shareholder base exchange ratio abbvie share outstanding allergan ordinary share close price share c represent preacquisition service portion fair value million abbvie stock option million rsus issue allergan equity award holder acquisition allergan account business combination acquisition method accounting acquisition method require thing asset acquire liability assume business combination recognize fair value acquisition date valuation asset acquire liability assume finalize second quarter measurement period adjustment preliminary purchase price allocation include increase intangible asset million ii increase defer income tax liability million iii individually insignificant adjustment net increase identifiable net asset million iv correspond decrease goodwill million measurement period adjustment primarily result completion valuation certain license agreement intangible asset base fact circumstance exist acquisition date result intervene event subsequent date adjustment significant impact abbvie result operation significant impact prior period result adjustment acquisition date follow table summarize final fair value asset acquire liability assume acquisition date million asset acquire liability assume cash equivalent shortterm investment account receivable inventory prepaid expense current asset investment property equipment intangible asset definitelive intangible asset inprocess research development noncurrent asset shortterm borrowing current portion longterm debt finance lease obligation account payable accrue liability longterm debt finance lease obligation defer income taxis longterm liability total identifiable net asset goodwill total asset acquire liability assume fair value stepup adjustment inventory billion amortize cost product sell inventory sell customer fully amortize december intangible asset relate billion definitelive intangible asset billion iprd acquire definitelive intangible asset consist develop product right license agreement amortize weightedaverage estimate useful life approximately year estimate pattern economic benefit estimate fair value identifiable intangible asset determine income approach valuation technique provide estimate fair value asset base market participant expectation cash flow asset generate remain useful life significant assumption inherent development asset valuation include estimate net cash flow year asset product appropriate discount rate necessary measure risk inherent future cash flow stream life cycle asset potential regulatory commercial success risk competitive trend impact asset cash flow stream factor form kthe fair value longterm debt determine quote market price acquisition date total purchase price adjustment billion amortize reduction interest expense net life relate debt goodwill calculate excess consideration transfer net asset recognize represent future economic benefit arise asset acquire individually identify separately recognize specifically goodwill recognize acquisition allergan represents value additional growth platform expand revenue base anticipate operational synergy cost saving creation single combine global organization goodwill deductible tax purpose follow acquisition date operating result allergan include consolidated financial statement period acquisition date december net revenue attributable allergan billion operating loss attributable allergan billion inclusive billion intangible asset amortization billion inventory fair value stepup amortization acquisitionrelate expense comprise primarily regulatory financial advisory legal fee total million year end december include sga expense consolidate statement earning fourth quarter abbvie recover certain acquisitionrelate regulatory fee total million record reduction sga expense consolidate statement earning year end december pro forma financial information follow table present unaudited pro forma combine result abbvie allergan acquisition allergan occur january year end december million net revenue net earning unaudite pro forma combine financial information prepare acquisition method accounting base historical financial information abbvie allergan order reflect occurrence acquisition january require unaudited pro forma financial information include adjustment reflect incremental amortization expense incur base final fair value identifiable intangible asset acquire incremental cost product sell relate fair value adjustment associate acquisition date inventory additional interest expense associate issuance debt finance acquisition reclassification acquisitionrelate cost incur year end december year end december unaudited pro forma financial information necessarily indicative consolidated result operation acquisition complete january addition unaudite pro forma financial information projection future result operation combine company reflect expect realization synergy cost saving associate acquisition licensing acquisition activity cash outflow related acquisition investment total million billion billion abbvie record acquire iprd milestone expense million billion billion significant arrangement impact require contingent milestone payment summarize syndesi therapeutics sa february abbvie acquire syndesi therapeutic sa portfolio novel modulator synaptic vesicle protein include lead molecule sdi account transaction asset acquisition sdi small molecule currently phase b study evaluate target nerve terminal enhance synaptic efficiency term agreement abbvie upfront payment million record acquire iprd milestone expense consolidate statement earning quarter agreement include additional future payment million achievement certain development regulatory commercial milestone juvise pharmaceuticals june abbvie laboratory juvise pharmaceutical juvise enter asset purchase agreement juvise acquire worldwide commercial right mature brand pylera treatment peptic ulcer infection bacterium helicobacter pylori transaction account sale asset completion transaction abbvie receive net cash proceed million recognize pretax gain million record operating income consolidate statement earning second quarter calico life sciences llc july abbvie calico life sciences llc calico enter extension collaboration discover develop bring market new therapy patient agerelate disease include neurodegeneration cancer second collaboration extension build partnership establish extended term agreement abbvie calico contribute additional million term extend additional year abbvie contribution payable equal installment begin calico responsible research early development advance collaboration project phase follow completion phase study abbvie option exclusively license collaboration compound exercise abbvie responsible latestage development commercial activity collaboration cost profit share equally party post option exercise quarter abbvie record million operate expense consolidated statement earning relate commitment agreement teneoone tnbb september abbvie acquire teneoone affiliate teneobio inc tnbb bcmatargete immunotherapeutic potential treatment relapse refractory multiple myeloma rr mm february abbvie teneoone enter strategic transaction develop commercialize tnb b bispecific antibody simultaneously target bcma cd design direct body immune system target kill bcmaexpresse tumor cell abbvie exercise exclusive right acquire teneoone tnbb base interim analysis ongoing phase study account transaction asset acquisition term agreement abbvie exercise payment million record acquire iprd milestone expense consolidate statement earning quarter agreement include additional payment million achievement certain development regulatory commercial milestone regenxbio inc september abbvie regenxbio inc regenxbio enter collaboration develop commercialize rgx investigational gene therapy wet agerelate macular degeneration diabetic retinopathy chronic retinal disease collaboration provide abbvie exclusive global license develop commercialize rgx regenxbio responsible completion ongoing trial abbvie regenxbio collaborate share cost additional trial abbvie lead clinical development commercialization rgx globally regenxbio abbvie share equally pretax profit net revenue rgx abbvie pay regenxbio tiere royalty net revenue outside close fourth quarter abbvie upfront payment million exclusively license rgx record acquire iprd milestone expense consolidated statement earning year end december agreement include additional payment billion achievement certain development regulatory commercial milestone imab biopharma september abbvie imab biopharma imab enter collaboration agreement development commercialization lemzoparlimab anticd monoclonal antibody internally discover develop imab treatment multiple cancer company collaborate design conduct global clinical trial evaluate lemzoparlimab collaboration provide abbvie exclusive global license exclude great china develop commercialize lemzoparlimab company share manufacturing responsibility abbvie primary manufacturer global supply agreement allow potential collaboration future cdrelate therapeutic agent subject license explore relate program respective territory term arrangement include initial upfront payment million exclusively license lemzoparlimab milestone payment million base phase result total million record acquire iprd milestone expense consolidate statement earning fourth quarter regulatory approval form ktransaction addition imab eligible receive billion achievement certain clinical development regulatory commercial milestone abbvie pay tiere royalty lowtomid teen percentage global net revenue outside great china genmab june abbvie genmab genmab enter collaboration agreement jointly develop commercialize genmab earlystage investigational bispecific antibody therapeutic enter discovery research collaboration future differentiate antibody therapeutic treatment cancer term agreement genmab grant abbvie exclusive license epcoritamab duobodycdxcd duohexabodycd duobodycdxt program epcoritamab company share commercial responsibility japan abbvie responsible global commercialization genmab record net revenue japan party share equally pretax profit sale genmab receive tiere royalty remain global sale discovery research partnership genmab conduct phase study program abbvie retain right optin program development abbvie upfront payment million record acquire iprd milestone expense consolidate statement earning abbvie additional payment billion achievement certain development regulatory commercial milestone program arrangement addition significant arrangement describe abbvie enter arrangement result charge relate upfront payment million million million connection individually insignificant earlystage arrangement enter abbvie additional payment billion achievement certain development regulatory commercial milestone acquire iprd milestone expense include development milestone million million million note collaboration company ongoing transaction entity collaboration agreement following represent significant collaboration agreement impact collaboration janssen biotech inc december pharmacyclic whollyowne subsidiary abbvie enter worldwide collaboration license agreement janssen biotech inc affiliates janssen janssen pharmaceutical companies johnson johnson joint development commercialization imbruvica novel orally active selective covalent inhibitor bruton tyrosine kinase certain compound structurally relate imbruvica oncology indication exclude immune inflammatory mediate disease condition psychiatric psychological disease conditions united states outside united states collaboration provide janssen exclusive license commercialize imbruvica outside united states coexclusively abbvie united states party responsible development manufacturing marketing product generate result collaboration collaboration set duration specific expiration date provide potential future development regulatory approval milestone payment million abbvie collaboration include cost sharing arrangement associate collaboration activity certain case janssen responsible approximately collaboration development cost abbvie responsible remain collaboration development cost united states party coexclusive right commercialize product abbvie principal endcustomer product sale abbvie janssen share pretax profit loss equally commercialization product sale imbruvica include abbvie net revenue janssen share profit include abbvie cost product sell cost incur collaboration report respective expense line item net janssen share outside united states janssen responsible exclusive right commercialize imbruvica abbvie janssen share pretax profit loss equally commercialization product abbvie share profit include abbvie net revenue cost incur collaboration report respective expense line item net janssen share follow table show profit cost sharing relationship janssen abbvie year end december millions united states janssen share profit include cost product sell international abbvie share profit include net revenue global abbvie share cost include respective line item abbvie receivable janssen include account receivable net million december million december abbvie payable janssen include account payable accrue liability million december million december collaboration genentech inc abbvie genentech inc genentech member roche group party collaboration license agreement execute jointly research develop commercialize human therapeutic product contain bcl inhibitor certain compound inhibitor include venclexta bcl inhibitor treat certain hematological malignancy abbvie share equally genentech pretax profit loss development commercialization venclexta united states abbvie pay royalties venclexta net revenue outside united states abbvie manufacture distribute venclexta globally principal endcustomer product sale sale venclexta include abbvie net revenue genentech share united states profit include abbvie cost product sell abbvie record sale marketing cost associate united states collaboration sga expense global development cost rd expense net genentech share royalty pay venclexta revenue outside united states include abbvie cost product sell follow table show profit cost sharing relationship genentech abbvie year end december millions genentech share profit include royalty include cost product sell abbvie share sale marketing cost collaboration include sga abbvie share development cost include rd form knote goodwill intangible asset goodwill follow table summarize change carry goodwill million balance december additionsa measurement period adjustmentsb foreign currency translation adjustment balance december additionsc foreign currency translation adjustment balance december goodwill addition relate acquisition soliton fourth quarter note b measurement period adjustment record related acquisition allergan note c goodwill addition relate acquisition djs fourth quarter note company perform annual goodwill impairment assessment quarter early impairment indicator exist december accumulate goodwill impairment loss intangible asset net follow table summarize intangible asset gross net gross net december carry accumulate carrying carry accumulate carry million amortization amortization definitelive intangible asset develop product right license agreement total definitelive intangible asset indefinitelive intangible asset total intangible asset net definitelive intangible asset september company strategic decision reduce ongoing sale marketing investment relate vuity onmarket product treat presbyopia strategic decision contribute significant decrease estimate future cash flow product represent trigger event require company evaluate underlie definite livedintangible asset impairment company utilize discount cash flow analysis estimate fair value intangible asset result impairment gross net carrying base revise cash flow company record pretax impairment charge million cost product sell consolidated statement earning quarter definitelive intangible asset amortize estimate useful life range year average year develop product right year license agreement amortization expense billion billion billion include cost product sell consolidated statement earning anticipate annual amortization expense definitelive intangible asset record december follow billion anticipate annual amortization expense indefinitelive intangible asset indefinitelive intangible asset represent acquire iprd associate product receive regulatory approval indefinitelive intangible asset december primarily relate acquisition allergan djs company perform annual impairment assessment indefinitelive intangible asset quarter early impairment indicator exist note integration restructuring plan allergan integration plan follow close allergan acquisition abbvie implement integration plan design reduce cost integrate optimize combine organization incur total cumulative charge billion cost consist severance employee benefit cost cash severance noncash severance include accelerated equity award compensation expense retention termination benefit integration expense follow table summarize charge benefit associate allergan acquisition integration plan severance employee benefit integration year end december million cost product sell research development sell general administrative total charge benefit follow table summarize cash activity record liability associate integration plan severance year end december million employee benefit integration charge payment adjustment accrue balance december charge payment adjustment accrue balance december charge benefit payment adjustment accrue balance december restructuring abbvie continuously evaluate operation identify opportunity optimize manufacturing rd operation commercial infrastructure administrative cost respond change business environment result abbvie management periodically approve individual restructuring plan achieve objective plan individually significant restructuring charge record million million million primarily relate employee severance contractual obligation charge record cost product sell rd expense sga expense consolidate statement earning base classification affect employee operation form kthe follow table summarize cash activity restructuring reserve millions accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december note lease abbvie lease portfolio primarily consist real estate property vehicle equipment follow table summarize amount location operating finance lease consolidate balance sheet december million balance sheet caption asset operate asset finance property equipment net total lease asset liability operate current account payable accrue liability noncurrent longterm liability finance current current portion longterm debt finance lease obligation noncurrent longterm debt finance lease obligation total lease liability follow table summarize lease cost recognize consolidated statement earning year end december million operating lease cost shortterm lease cost variable lease cost total lease cost december company enter agreement sublease portion madison new jersey office space end original lease maturity result agreement company recognize impairment loss rightofuse asset million wroteoff relate leasehold improvement million loss record sga expense consolidated statement earning year end december company discount cash flow method value rightofuse asset determine impairment sublease income finance lease cost insignificant follow table present weightedaverage remain lease term weightedaverage discount rate operating finance lease year end december weightedaverage remain lease term year operating finance weightedaverage discount rate operating finance follow table present supplementary cash flow information company lease year end december million cash pay amount include measurement lease liability operate cash flow operating lease rightofuse asset obtain exchange new operating lease liability finance lease cash flow insignificant rightofuse asset obtain exchange new operating lease liability december include million rightofuse asset acquire allergan acquisition follow table summarize future maturity abbvie operating finance lease liability december operating finance million lease lease total total lease payment interest present value lease liability lease payment recognize lease liability optional renewal period insignificant form knote debt credit facility commitment contingency follow table summarize longterm debt effective effective december dollar million interest rate interest rate aggregate note senior note senior note float rate term loan senior euro note principal senior note senior note senior euro note principal senior note senior euro note principal senior note senior note float rate term loan float rate term loan senior note senior note senior euro note principal senior note senior euro note principal senior euro note principal senior note senior euro note principal senior euro note principal senior note senior note senior note senior note senior note senior note senior note senior note senior note senior note senior note senior note fair value hedge unamortized bond discount unamortize deferred financing cost unamortized bond premium b total longterm debt finance lease obligation current portion noncurrent portion exclude effect related interest rate swap b represent unamortized purchase price adjustment allergan debt senior note float rate term loan redeemable prior maturity redemption price equal principal plus makewhole premium abbvie redeem debt security par generally month prior maturity december company compliance senior note covenant term loan covenant maturitie longterm debt year end december million total obligation commitment fair value hedge unamortized bond premiumsdiscount defer financing cost finance lease obligation total longterm debt finance lease obligation repayment issuance longterm debt company repay billion aggregate principal senior note billion aggregate principal senior note billion aggregate principal senior note repayment exercise term note range day early redemption principal quarter end december company pay billion aggregate principal senior note billion aggregate principal senior note million aggregate principal float rate senior note maturity additionally company refinance billion float rate fiveyear term loan refinance company repay exist billion term loan borrow billion new term loan lower float rate significant term loan include maturity date remain unchanged refinance subsequent december company repay billion float rate threeyear term loan schedule mature company repay billion aggregate principal senior note million aggregate principal senior euro note billion aggregate principal senior note repayment exercise term note range day early redemption principal amount company repay billion aggregate principal senior note billion aggregate principal senior note billion aggregate principal float rate senior note maturity additionally company refinance billion float rate threeyear term loan refinance company repay exist billion term loan borrow billion new term loan lower float rate significant term loan include maturity date remain unchanged refinance shortterm borrowing commercial paper borrowing outstanding december december commercial paper borrowing issue commercial paper borrowing issue weightedaverage interest rate abbvie currently billion fiveyear revolve credit facility mature august credit facility enable company borrow fund unsecured basis variable interest rate contain covenant company compliance december commitment fee abbvie revolve credit facility insignificant amount outstanding company credit facility december december contingency guarantee connection separation abbvie indemnify abbott liability result operation abbvie business income tax liability respect period prior distribution date liability agree abbvie abbott abbvie material exposure balance sheet arrangement specialpurpose entity ordinary course business abbvie periodically enter thirdparty agreement assignment product right result abbvie secondarily liable obligation abbvie previously primarily liable base past experience likelihood payment agreement remote form knote financial instrument fair value measure risk management policy company expose foreign currency exchange rate interest rate risk relate business operation abbvie hedge policy attempt manage risk acceptable level base company judgment appropriate tradeoff risk opportunity cost company use derivative nonderivative instrument reduce exposure foreign currency exchange rate abbvie periodically enter interest rate swap company agree exchange specify interval difference fix float interest amount calculate reference agreedupon notional derivative instrument trading purpose manage exposure change interest rate investment security company outstanding derivative instrument contain credit risk relate contingent feature collateral generally require financial instrument abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate intercompany transaction denominate currency functional currency local entity contract notional amount total billion december billion december designate cash flow hedge record fair value duration forward exchange contract generally month accumulate gain loss december reclassify aoci include cost product sell time product sell generally exceed month date settlement company enter treasury rate lock agreement notional amount total billion hedge exposure variability future cash flow result change interest rate relate issuance longterm debt connection acquisition allergan treasury rate lock agreement designate cash flow hedge record fair value agreement net settle issuance senior note result net gain recognize comprehensive income gain reclassify interest expense net term relate debt company party interest rate swap contract designate cash flow hedge mature november notional million december effect hedge contract change floatingrate interest obligation fix rate portion float rate debt realize unrealized gain loss include aoci reclassify interest expense net life floatingrate debt company enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables intercompany loan contract designate hedge record fair value result gain loss reflect net foreign exchange loss consolidate statement earning generally offset loss gain foreign currency exposure manage contract notional amount total billion december billion december company use foreign currency forward exchange contract foreign currency denominate debt hedge net investment certain foreign subsidiary affiliate company aggregate principal senior euro note designate net investment hedge billion december december addition company foreign currency forward exchange contract designate net investment hedge notional amount total billion sek billion cad million chf million december billion december company use spot method assess hedge effectiveness derivative instrument designate net investment hedge realize unrealized gain loss hedge include aoci initial fair value hedge component exclude assessment effectiveness recognize interest expense net life hedge instrument company party interest rate swap contract designate fair value hedge notional amount total billion december december effect hedge contract change fixedrate interest obligation float rate portion debt abbvie record contract fair value adjust carry fixedrate debt offset amount exclude assessment effectiveness cash flow hedge fair value hedge follow table summarize amount location abbvie derivative instrument consolidate balance sheet fair value fair value derivative asset position derivative liability position balance sheet balance sheet december million caption caption foreign currency forward exchange contract prepay expense account payable designate cash flow hedge accrue liability longterm designate cash flow hedge asset liability designate net investment prepaid expense account payable hedge accrue liability designate net investment longterm hedge asset liability prepay expense account payable designate hedge accrue liability interest rate swap contract prepay expense account payable designate cash flow hedge accrue liability prepay expense account payable designate fair value hedge accrue liability longterm designate fair value hedge asset liability total derivative certain derivative subject netting arrangement company counterpartie company offset derivative asset liability consolidated balance sheet follow table present pretax amount gain loss derivative instrument recognize comprehensive income year end december million foreign currency forward exchange contract designate cash flow hedge designate net investment hedge interest rate swap contract designate cash flow hedge assume market rate remain constant contract maturity company expect reclassify pretax gain million cost product sell foreign currency cash flow hedge pretax gain million interest expense net treasury rate lock agreement cash flow hedge month related abbvie nonderivative foreign currency denominate debt designate net investment hedge company recognize comprehensive income pretax gain million pretax gain million pretax loss million form kthe follow table summarize pretax amount location derivative instrument net gain loss recognize consolidated statement earning include net gain loss reclassify aoci net earning note net gain loss reclassify aoci year end december million statement earning caption foreign currency forward exchange contract designate cash flow hedge cost product sell designate net investment hedge interest expense net designate hedge net foreign exchange loss treasury rate lock agreement designate cash flow hedge interest expense net interest rate swap contract designate cash flow hedge interest expense net designate fair value hedge interest expense net debt designate hedged item fair value hedge interest expense net fair value measure fair value hierarchy consist follow level level valuation base unadjusted quote price active market identical asset company ability access level valuation base quote price similar instrument active market quote price identical similar instrument market active modelbase valuation significant input observable market level valuation significant input unobservable market include use judgment company management assumption market participant use price asset liability follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price significant active market observable significant identical asset input unobservable input million total level level level asset cash equivalent money market fund time deposit debt security equity security foreign currency contract total asset liabilitie interest rate swap contract foreign currency contract contingent consideration total liability follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price significant active market identical observable significant asset input unobservable input million total level level level asset cash equivalent money market fund time deposit debt security equity security interest rate swap contract foreign currency contract total asset liabilitie interest rate swap contract foreign currency contract contingent consideration total liability money market fund time deposit value relevant observable market input include quote price similar asset interest rate curve equity security primarily consist investment fair value determine publish market price unit multiply number unit hold consideration transaction cost derivative enter company value observable market input include publish interest rate curve forward spot price foreign currency fair value measurement contingent consideration liability determine base significant unobservable input include discount rate estimate probability time achieve specify development regulatory commercial milestone estimate future sale acquire product potential contingent consideration payment estimate apply probabilityweighte expect payment model contingent milestone payment monte carlo simulation model contingent royalty payment discount present value change fair value contingent consideration liability result change number input include discount rate probability achieve milestone time require achieve milestone form kand estimate future sale significant judgment employ determine appropriateness certain input change input describe material impact company financial position result operation give period fair value company contingent consideration liability calculate follow significant unobservable input year end december million range weight averagea range weight averagea discount rate probability payment unachieve milestone probability payment royalty indicationb project year payment unobservable input weight relative fair value contingent consideration liability b exclude approve indication estimate probability payment december range december transfer asset liability level fair value hierarchy follow table present change fair value contingent consideration liability measure level input year end december million begin balance additionsa change fair value recognize net earning payment end balance addition year end december represent contingent consideration liability assume djs acquisition addition year end december represent contingent consideration liability assume allergan luminera acquisition note change fair value recognize net earning record expense net consolidated statement earning include charge billion billion billion change fair value reflect higher estimate skyrizi sale drive strong market share uptake passage time partially offset high discount rate change fair value reflect higher estimate skyrizi sale drive strong market share uptake favorable clinical trial result passage time partially offset high discount rate change fair value reflect higher estimate skyrizi sale drive strong market share uptake low discount rate passage time favorable clinical trial result certain financial instrument carry historical cost basis fair value book value approximate fair value basis measure approximate fair value certain financial instrument december show table basis fair value measurement quote price active market identical significant significant approximate fair asset observable input unobservable input million book value value level level level liability shortterm borrowing current portion longterm debt finance lease obligation exclude fair value hedge longterm debt finance lease obligation exclude fair value hedge total liability book value approximate fair value basis measure approximate fair value certain financial instrument december show table basis fair value measurement quote price active market identical significant significant approximate fair asset observable input unobservable input million book value value level level level liability shortterm borrowing current portion longterm debt finance lease obligation exclude fair value hedge longterm debt finance lease obligation exclude fair value hedge total liability abbvie hold investment equity security readily determinable fair value company record investment cost remeasure fair value base certain observable price change impairment event occur carry investment million december million december significant cumulative upward downward adjustment record investment december concentration risk total net account receivable wholesaler account december december substantially abbvie pharmaceutical product net revenues united states wholesaler humira adalimumab abbvie single large product account approximately abbvie total net revenue form knote postemployment benefit abbvie sponsor pension postemployment benefit plan include define benefit define contribution termination indemnity plan cover employee worldwide addition abbvie provide medical benefit primarily eligible retiree united states puerto rico postretirement benefit plan net obligation plan reflect consolidated balance sheet december follow table summarize benefit plan information global abbviesponsore define benefit postemployment plan define benefit plan postemployment plan year end december millions project benefit obligation begin period service cost interest cost employee contribution amendment actuarial gain loss benefit pay primarily foreign currency translation adjustment end period fair value plan asset begin period actual return plan asset company contribution employee contribution benefit pay primarily foreign currency translation adjustment end period fund status end period amount recognize consolidated balance sheet asset account payable accrue liability longterm liability net obligation actuarial loss net prior service cost credit accumulate comprehensive loss relate international define benefit plan project benefit obligation table include billion december billion december plan reflect table accumulate benefit obligation billion december billion december actuarial gain billion qualified pension plan actuarial gain million postemployment plan primarily drive increase discount rate actuarial gain million qualified pension plan actuarial loss million post employment plan primarily drive increase assume discount rate offset change demographic assumption information pension plan accumulate benefit obligation excess plan asset december millions accumulate benefit obligation fair value plan asset information pension plan project benefit obligation excess plan asset december millions project benefit obligation fair value plan asset abbvie pension plan modify close plan new entrant effective january addition change abbvie retiree health benefit plan approve communicate employee retiree october begin medicareeligible retiree medicare eligible dependent choose health care coverage insurance provider private medicare exchange abbvie continue provide financial support medicareeligible retiree change retiree health benefit plan decrease abbvie postemployment benefit obligation increase abbvie unrecognized prior service credit december million form kamount recognize comprehensive income follow table summarize pretax loss gain include comprehensive income year end december millions define benefit plan actuarial loss gain amortization prior service cost amortization actuarial loss foreign exchange loss gain total loss gain postemployment plan actuarial loss gain prior service credit amortization prior service credit amortization actuarial loss total loss gain net periodic benefit cost year end december millions define benefit plan service cost interest cost expect return plan asset amortization prior service cost amortization actuarial loss net periodic benefit cost postemployment plan service cost interest cost amortization prior service credit amortization actuarial loss net periodic benefit cost component net periodic benefit cost service cost include expense net consolidated statement earning weightedaverage assumption determine benefit obligation measurement date december define benefit plan discount rate rate compensation increase cash balance interest credit rate postemployment plan discount rate assumption calculate december measurement date benefit obligation calculation net periodic benefit cost weightedaverage assumption determine net periodic benefit cost year end december define benefit plan discount rate determine service cost discount rate determine interest cost expect longterm rate return plan asset expect rate change compensation cash balance interest credit rate postemployment plan discount rate determine service cost discount rate determine interest cost december postretirement health care obligation remeasurement company assume pre post annual rate increase capita cost cover health care benefit pre rate assume decrease gradually post remain level purpose measure postretirement health care cost company assume pre post annual rate increase capita cost cover health care benefit pre rate assume decrease gradually post remain level form kdefine benefit pension plan asset basis fair value measurement quote price active market significant significant unobservable identical asset observable input input december millions level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real asset otherf total total asset measure nav fair value plan asset basis fair value measurement quote price active market significant significant unobservable identical asset observable input input december millions level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real asset otherf total total asset measure nav fair value plan asset mix index fund actively manage equity account benchmarke large cap indice b mix index fund actively manage equity account benchmarke mid cap indice c mix index fund actively manage equity account benchmarke nonus equity index develop emerge market security hold actively manage account index fund mutual fund e primarily fund global mandate flexibility allocate capital broadly wide range asset class strategy include limited equity fix income commodity financial future currency security objective outperform agree benchmark specific return volatility target f investment cash cash equivalent equities register investment company quote price value publish market price fix income security value significant observable input quote price obtain independent financial service industryrecognize vendor investment hold pool investment fund common collective trust limited partnership value net asset value nav practical expedient estimate fair value nav provide fund administrator base value underlie asset own fund minus liability investment mix equity security fix income asset allocation strategy base achieve desire return balance high return volatile equity security low return volatile fix income security investment allocation establish plan generally range market industry sector capitalization size case fix income security maturity credit quality target investment allocation abbvie pension plan equity security fix income security asset allocation strategy holding know significant concentration risk plan asset abbvie pension plan plan expect return plan asset assumption plan base management expectation longterm average rate return achieve underlying investment portfolio establish assumption management consider historical expect return asset class plan invest current economic capital market condition expect benefit payment follow table summarize total benefit payment expect pay plan participant include payment fund plan company asset define year end december million benefit plans postemployment plan define contribution plan abbvie maintain define contribution saving plan benefit eligible employee expense recognize plan million million million abbvie provide certain postemployment benefit primarily salary continuation arrangement qualify employee accrue related cost service live employee note equity stockbase compensation stockholder company approve abbvie amend restate incentive stock program amend plan amend restates abbvie incentive stock program isp abbvie grant stockbase award eligible employee pursuant amend plan provide different form benefit include nonqualified stock option rsus performancebase award amend plan total million share abbvie common stock reserve issuance award abbvie employee form kabbvie measure compensation expense stockbase award base grant date fair value award estimate number award expect vest forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate compensation cost stockbase award amortize service period shorter vest period employee retirement eligible retirement eligible employee generally age old year service stockbase compensation expense principally relate award issue pursuant isp amend plan summarize follow year end december million cost product sell research development sell general administrative pretax compensation expense tax benefit aftertax compensation expense realize excess tax benefit associate stockbase compensation total million million million stock option stock option award employee typically contractual term year generally vest onethird increment threeyear period exercise price equal market value date grant fair value determine blackschole model weightedaverage grantdate fair value stock option grant connection allergan acquisition second quarter abbvie issue million stock option holder allergan option result conversion option option fairvalue lattice valuation model refer note additional information allergan acquisition follow table summarize abbvie stock option activity weightedaverage weight average remain aggregate intrinsic option thousand aggregate intrinsic value million option exercise price life year value outstanding december grant exercise lapse forfeit outstanding december exercisable december total intrinsic value option exercise million million million total fair value option vest million december million unrecognized compensation cost relate stock option expect recognize expense approximately year rsus performance share rsus award employee senior executive key employee generally vest ratable increment fouryear period recipient rsus entitle receive dividend equivalent dividend declare pay rsu vest period majority equity award abbvie grant senior executive key employee performancebase equity award grant senior executive key employee consist combination performanceveste rsus performance share nonqualified stock option describe performanceveste rsus potential vest onethird increment threeyear performance period earn base abbvie return invest capital roic performance relative define peer group pharmaceutical biotech life science company recipient receive share abbvie common stock vest award performance share potential vest threeyear performance period earn base abbvie ep achievement abbvie total stockholder return tsr market condition relative define peer group pharmaceutical biotech life science company dividend equivalent performanceveste rsus performance share accrue performance period payable vest extent share earn weightedaverage grantdate fair value rsus performance share generally determine base number sharesunit grant quote price abbvie common stock date grant weightedaverage grantdate fair value performance share tsr market condition determine monte carlo simulation model follow table summarize abbvie rsu performance share activity weightedaverage grant share unit thousand share unit date fair value outstanding december grant vest forfeited outstanding december fair market value rsus performance share applicable vested billion million million connection allergan acquisition second quarter abbvie issue million rsus holder allergan equity award base conversion factor describe transaction agreement refer note additional information allergan acquisition december million unrecognized compensation cost relate rsus performance share expect recognize expense approximately year cash dividend cash dividend declare common share total follow table summarize quarterly cash dividend declare date payment dividend date payment dividend date payment dividend declare date share declare date share declare date share stock repurchase program company stock repurchase authorization permit purchase abbvie share time time openmarket private transaction management discretion program time limit discontinue time share repurchase program record acquisition cost include related expense available general corporate purpose abbvie repurchase million share billion million share million million share million abbvie remain stock repurchase authorization billion december february abbvie board director authorize billion increase exist stock repurchase authorization form kaccumulate comprehensive loss follow table summarize change component accumulate comprehensive loss net tax pension foreign currency net investment postemployment cash flow million bracket denote loss translation adjustment hedge activity benefit hedge activity total balance december comprehensive income loss reclassification net loss gain reclassify accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassification net loss gain reclassify accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassification net loss gain reclassify accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income include pension postemployment benefit plan gain billion primarily actuarial gain drive high discount rate partially offset loss plan asset comprehensive income include foreign currency translation adjustment total loss million principally impact weaken euro translation company eurodenominate asset offset impact net investment hedging activity total gain million comprehensive income include foreign currency translation adjustment total loss billion principally impact weaken euro translation company eurodenominate asset offset impact net investment hedging activity total gain million comprehensive income include foreign currency translation adjustment total gain billion principally impact strengthen euro translation company euro denominate asset offset impact net investment hedging activity total loss million table present impact abbvie consolidated statement earning significant amount reclassify component accumulate comprehensive loss year end december million bracket denote gain net investment hedging activity gain derivative exclude effectiveness testinga tax expense total reclassification net tax pension postemployment benefit amortization actuarial loss otherb tax benefit total reclassification net tax cash flow hedging activity loss gain foreign currency forward exchange contractsc gain treasury rate lock agreementsa loss interest rate swap contractsa tax expense benefit total reclassification net tax amount include interest expense net note b amount include computation net periodic benefit cost note c amount include cost product sell note addition common stock abbvie authorize capital include million share prefer stock par value december share prefer stock issue outstanding form knote income taxis earning income tax expense year end december million domestic foreign total earning income tax expense income tax expense year end december million current domestic foreign total current taxis defer domestic foreign total defer taxis total income tax expense benefit effective tax rate reconciliation year end december statutory tax rate effect foreign operation tax credit impact relate tax reform nondeductible expense tax law change related restructure tax audits settlement net effective tax rate effective income tax rate fluctuate year year allocation company taxable earning jurisdiction certain discrete factor event year include change tax law acquisition collaboration effective income tax rate differ statutory tax rate principally impact foreign operation reflect impact low income tax rate location outside united states tax incentive puerto rico foreign tax jurisdiction business development activity change enact tax rate law relate restructure tax audits settlement change fair value contingent consideration effective tax rate period reflect benefit tax credit principally relate research development credit orphan drug tax credit puerto rico excise tax credit puerto rico tax credit relate excise tax certain product manufacture puerto rico tax levy gross inventory purchase entities puerto rico include cost product sell consolidated statement earning majority tax creditable income tax purpose puerto rico enact act puerto rico act allow transition puerto rico excise tax levy gross inventory purchase incomebase tax begin company complete transition requirement puerto rico act result remeasurement certain defer tax asset liability base income tax rate expect reverse future net tax benefit remeasurement defer taxis relate puerto rico act million effective income tax rate include recognition net tax benefit billion relate change tax law relate restructuring include certain intragroup transfer intellectual property defer tax remeasurement tax cut job act act sign law december result significant change corporate tax system include time transition tax mandatory deem repatriation earning certain foreign subsidiary previously untaxe act create minimum tax certain foreign source earning company account policy minimum tax foreign source earning report tax effect basis minimum tax recognize tax expense year incur period expense defer tax asset liability december millions defer tax asset compensation employee benefit accrual reserve chargeback rebate advance payment net operating loss carryforward total defer tax asset valuation allowance total net defer tax asset defer tax liability excess book basis tax basis intangible asset excess book basis tax basis investment total defer tax liability net defer tax asset liability increase net defer tax asset primarily related capitalization rd expense increase accrual reserve offset decrease advance payment decrease defer tax liability primarily relate amortization intangible asset connection allergan acquisition company record adjustment measurement period relate foreign net operating loss credit carryforward expect realize adjustment reflect increase billion defer tax asset offset increase valuation allowance result net impact defer tax asset company valuation allowance billion december billion december principally relate foreign state net operating loss credit carryforward expect realize december company federal state foreign credit carryforward million federal state foreign net operating loss carryforward billion expire time remain federal foreign loss carryforward billion expiration act significantly change time manner earning foreign subsidiary subject tax unremitted foreign earning subject act transition tax consider indefinitely reinveste post earning subject minimum tax foreign source earning eligible percent foreign dividend receive deduction consider indefinitely reinveste earning company generally consider instance outside basis difference foreign subsidiary incur additional tax reversal eg capital gain distribution permanent duration unrecognized tax liability practicable determine form kunrecognize tax benefit year end december million begin balance increase acquisition increase current year tax position increase prior year tax position decrease prior year tax position settlement lapse statute limitation end balance recognize net potential tax benefit impact company effective tax rate billion billion increase current year tax position increase prior year tax position table include amount related federal state international tax item increase acquisition table include amount related federal state international tax item record acquisition accounting relate allergan acquisition abbvie recognize interest penalty relate income tax matter income tax expense consolidated statement earning abbvie recognize gross income tax expense million million million interest penalty relate income tax matter abbvie accrual payment gross interest penalty billion december million december million december company routinely audit tax authority significant jurisdiction number audits currently underway reasonably possible month uncertain tax position settle result decrease gross unrecognized tax benefit potential resolution federal state foreign examination expiration statute limitation company gross unrecognized tax benefit balance change month million significant federal state local international matter conclude year company believe adequate provision income tax uncertainty note legal proceeding contingency abbvie subject contingency claim legal proceeding investigation product liability intellectual property commercial security matter arise normal course business significant matter describe loss contingency provision record probable loss management well estimate loss good estimate minimum loss contingency probable range record litigation matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue initiation new legal proceeding change status exist proceeding result change estimate loss accrue abbvie feasible predict outcome proceeding exposure certainty management believe ultimate disposition material adverse effect abbvie consolidated financial position result operation cash flow subject certain exception specify separation agreement abbott laboratories abbott abbvie abbvie assume liability control pende threatened legal matter relate business include liability claim legal proceeding relate product business discontinue prior distribution assume retain liability indemnify abbott liability arise result assume legal matter antitrust litigation lawsuit pende abbvie generally allege patent litigation settlement involve niaspan enter kos pharmaceuticals inc company acquire abbott presently subsidiary abbvie generic company violate federal state antitrust law state unfair deceptive trade practice unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee lawsuit pende federal court consist individual plaintiff lawsuit consolidated purport class action bring niaspan direct purchaser bring niaspan endpayor case pende united states district court eastern district pennsylvania coordinate consolidated pretrial proceeding mdl rule niaspan antitrust litigation mdl august court certify class direct purchaser niaspan june august court deny endpayor motion certify class october orange county california district attorney office file lawsuit behalf state california niaspan patent litigation settlement orange county superior court assert claim unfair competition provision california business profession code seek injunctive relief restitution civil penalty attorney fee august direct purchaser androgel file lawsuit king drug co florence inc et al v abbvie inc et al abbvie united states district court eastern district pennsylvania allege patent litigation settlement relate agreement solvay pharmaceuticals inc company abbott acquire february know abbvie product llc generic company violate federal antitrust law allege patent litigation abbott generic company androgel sham litigation settlement litigation violate federal antitrust law plaintiff generally seek monetary damage andor injunctive relief attorney fee november state oregon file lawsuit multnomah county oregon circuit court make similar allegation patent litigation generic company lawsuit pende forest laboratory llc abbvie subsidiary generally allege patent litigation settlement involve namenda enter forest generic company conduct forest involve namenda violate state antitrust unfair deceptive trade practice unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee lawsuit purport class action file indirect purchaser namenda consolidated namenda indirect purchaser antitrust litigation united states district court southern district new york november party reach agreement settle matter receive preliminary court approval lawsuit pende forest laboratory llc generally allege patent litigation settlement involve bystolic generic manufacturer violate federal state antitrust law state unfair deceptive trade practice unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee lawsuit purport class action file behalf direct indirect purchaser bystolic consolidated bystolic antitrust litigation united states district court southern district new york government proceeding lawsuit pende allergan manufacturer generally allege improperly promote sell prescription opioid product approximately matter pende allergan federal court case consolidated pretrial purpose united states district court northern district ohio mdl rule national prescription opiate litigation mdl approximately matter pende state court plaintiff case include state county city municipal entity native american tribes union trust fund thirdparty payor private hospital personal injury claimant generally seek compensatory punitive damage november allergan finalized term settlement state local government entity native american tribe settlement subject certain condition include allergan determination sufficient number government entity elect participate settlement abbvie record charge billion sell general administrative expense consolidated statement earning second quarter relate potential settlement shareholder security litigation june lawsuit elliott associates lp et al v abbvie inc file investment fund abbvie cook county illinois circuit court allege abbvie misrepresentation omission connection propose transaction shire similar lawsuit file july october abbvie instance chief executive officer court additional investment fund september illinois court grant abbvie motion summary judgment pende claim pende case dismiss prejudice november illinois appellate court affirm summary judgment abbvie favor december court deny plaintiff petition rehear october federal securities lawsuit holwill v abbvie inc et al file united states district court northern district illinois abbvie chief executive officer chief financial officer allege reason state humira sale growth financial filing mislead omit allege misconduct connection humira patient reimbursement support service service item value allegedly induce humira prescription september court grant plaintiff motion certify class shareholder derivative lawsuit ranney v gonzalez et al file delaware chancery court allege form kcertain abbvie director officer breach fiduciary duty base related allegation december abbvie directorofficer defendant file motion dismiss plaintiff voluntarily dismiss lawsuit prejudice lawsuit pende allergan certain current officer allege misrepresentation omission allergan texture breast implant lawsuit file allergan shareholder consolidated united states district court southern district new york allergan plc security litigation plaintiff generally seek compensatory damage attorney fee september court partially grant allergan motion dismiss september court grant plaintiff motion certify class december court grant allergan motion summary judgment remain claim dismiss prejudice plaintiff appeal court motion dismiss summary judgment ruling april federal security lawsuit nakata v abbvie inc file united states district court northern district illinois abbvie certain officer allege misstatement potential effect safety information company product food drug administration approval labeling abbvie rinvoq july shareholder derivative lawsuit treppel family trust v gonzalez et al katcher v gonzalez et al file court allege certain abbvie director officer breach fiduciary legal duty base related allegation product liability general litigation qui tam lawsuit ex rel silbersher v allergan inc et al file united states district court northern district california allergan entity allege conduct patent office result false claim payment federal state healthcare payor namenda xr namzaric plaintiffrelator seek damage attorney fee federal false claim act state law analogue federal government state government decline intervene lawsuit august united states court appeal reverse district court denial allergan motion dismiss case remand district court proceeding consistent rule intellectual property litigation pharmacyclic llc wholly own subsidiary abbvie seek enforce patent right relate ibrutinib tablet drug pharmacyclic sell trademark imbruvica case file united states district court district delaware march alvogen pine brook llc natco pharma ltd august court issue decision hold assert patent infringe valid judgment preclude defendant obtain regulatory approval launch patent expire august defendant appeal november court appeal federal circuit affirm judgment janssen biotech inc global collaboration pharmacyclic concern development marketing imbruvica coplaintiff suits abbvie inc seek enforce patent right relate venetoclax drug sell trademark venclexta litigation file united states district court district delaware july dr reddys laboratories ltd dr reddys laboratories inc alembic pharmaceuticals ltd alembic pharmaceuticals inc alembic global holding sa abbvie allege defendant propose generic venetoclax product infringe certain patent seek declaratory injunctive relief genentech inc global collaboration abbvie concern development marketing venclexta coplaintiff suit note segment geographic area information abbvie operate single global business segment dedicate research development manufacturing commercialization sale innovative medicine therapy operating structure enable chief executive officer chief operating decision maker codm allocate resource assess business performance global basis order achieve establish longterm strategic goal consistent structure global research development supply chain organization responsible discovery manufacturing supply product commercial effort coordinate marketing sale distribution product organize geographic region therapeutic area activity support global corporate administrative staff determination single business segment consistent consolidated financial information regularly review codm purpose assess performance allocate resource planning forecasting future period substantially abbvie net revenues united states wholesaler outside united states product sell primarily health care provider distributor depend market serve follow table detail abbvie worldwide net revenue year end december million immunology humira united states international total skyrizi united states international total rinvoq united states international total hematologic oncology imbruvica united states collaboration revenue total venclexta united states international total aesthetic botox cosmetic united states international total juvederm collection united states international total aesthetics united states international total neuroscience botox therapeutic united states international total vraylar united states international total duodopa united states international total ubrelvy united states qulipta united states neuroscience united states international total form kyear end december million eye care lumiganganfort united states international total alphagancombigan united states international total restasis united states international total eye care united states international total key product mavyret united states international total creon united states linzessconstella united states international total total net revenue net revenue include allergan product revenue acquisition closing date net revenue external customer geographic area base product shipment destination follow year end december millions united states germany canada japan china france australia spain united kingdom italy brazil country total net revenue longlive asset primarily net property equipment geographic area follow december millions united states puerto rico europe total longlive asset note fourth quarter financial result unaudite quarter end december millions share datum net revenue gross margin net earning attributable abbvie inc basic earning share attributable abbvie inc dilute earning share attributable abbvie inc cash dividend declare common share form kreport independent register public accounting firm stockholder board directors abbvie inc opinion financial statement audit accompany consolidated balance sheet abbvie inc subsidiary company december relate consolidated statement earning comprehensive income equity cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise current period audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate sale rebate accrual medicaid medicare manage care program description matter discuss note consolidated financial statement caption revenue recognition company establish provision sale rebate period relate product sell december company million sale rebate accrual large portion rebate provide pharmacy benefit manager state government medicaid programs insurance company administer medicare drug plan private entity medicaid medicare manage care program order establish sale rebate accrual company estimate rebate base identification product subject rebate applicable price rebate term estimate lag time sale payment rebate auditing medicaid medicare manage care sale rebate accrual complex require significant auditor judgment accrual consider multiple subjective complex estimate assumption estimate assumption include estimate inventory distribution channel impact lag time sale customer payment rebate final payer relate product sale impact applicable price rebate term derive estimate assumption company internal external source information estimate product distribution channel payer mix prescription volume historical experience management supplement historical datum analysis qualitative adjustment base change rebate trend rebate program contract term legislative change significant event indicate change reserve appropriate address obtain understanding evaluate design test operating effectiveness control matter audit company sale rebate accrual medicaid medicare manage care program include testing control management review significant assumption input estimation medicaid medicare manage care rebate include significant assumption discuss test inclusive management control evaluate accuracy reserve judgments actual rebate pay rebate validation processing control ensure datum evaluate support significant assumption complete accurate applicable verified external data source test sale rebate accrual medicaid medicare manage care program audit procedure include understand evaluate significant assumption underlie datum management calculation test significant assumption include corroboration external data source evaluate reasonableness assumption consider industry economic trend product profile regulatory factor assess historical accuracy management estimate compare actual activity previous estimate perform analytical procedure base internal external datum source evaluate completeness reserve medicaid involved specialist understand statutory reimbursement requirement assess consistency company calculation methodology applicable government regulation policy form kvaluation contingent consideration description matter discuss note consolidated financial statement caption business combination note caption fair value measure company recognize contingent consideration liability estimate fair value acquisition date connection apply acquisition method accounting business combination subsequent change fair value contingent consideration liability record consolidated statement earning period change december company million contingent consideration liability represent level fair value measurement fair value hierarchy significant unobservable input determine fair value use management judgment assumption market participant use pricing liability audit valuation contingent consideration liability complex require significant auditor judgment use monte carlo simulation model high degree subjectivity evaluate certain assumption require estimate fair value contingent royalty payment particular fair value measurement sensitive significant assumption underlie estimate future sale acquire product management utilize expertise industry include commercial dynamic trend utilization knowledge clinical development regulatory approval process determine certain assumption address obtain understand evaluate design test operating effectiveness control matter audit company contingent consideration liability process include management process establish significant assumption measure liability include testing control management review significant assumption input determination fair value testing inclusive key management review control monitor evaluate clinical development acquire product estimate future sale control ensure datum evaluate support significant assumption complete accurate applicable verified external data source test estimate fair value contingent consideration liability audit procedure include inspect term execute agreement assess monte carlo simulation model testing key contractual input significant assumption discuss evaluated assumption judgment consider observable industry economic trend standard external data source regulatory factor estimate amount future sale evaluate reasonableness relation internal external analysis clinical development progress timeline probability success benchmark regulatory notice procedure include evaluate data source management determine assumption necessary include evaluation available information corroborate contradict management conclusion involve valuation specialist assess company monte carlo simulation model perform corroborative fair value calculation ernst young llp serve company auditor chicago illinois february item change disagreement accountant account financial disclosure item control procedure disclosure control procedure internal control financial reporting evaluation disclosure control procedure chief executive officer richard gonzalez chief financial officer scott reents evaluate effectiveness abbvie disclosure control procedure end period cover report conclude abbvie disclosure control procedure effective ensure information abbvie require disclose report file submit securities exchange commission securities exchange act record process summarize report time period specify commission rule form ensure information require disclose abbvie report file submit securities exchange act accumulate communicate abbvie management include principal executive officer principal financial officer appropriate allow timely decision require disclosure change internal control financial reporting change abbvie internal control financial reporting define rule af securities exchange act materially affect reasonably likely materially affect abbvie internal control financial reporting quarter end december inherent limitation effectiveness control abbvie management include chief executive officer chief financial officer expect abbvie disclosure control internal control financial reporting prevent detect error fraud control system matter design operate provide reasonable absolute assurance control system objective meet design control system reflect fact resource constraint benefit control consider relative cost inherent limitation control system evaluation control provide absolute assurance misstatement error fraud occur control issue instance fraud detect inherent limitation include reality judgment decisionmake faulty breakdown occur simple error mistake control circumvent individual act person collusion people management override control design system control base certain assumption likelihood future event assurance design succeed achieve state goal potential future condition projection evaluation control effectiveness future period subject risk time control inadequate change condition deterioration degree compliance policy procedure management annual report internal control financial reporting management abbvie responsible establish maintain adequate internal control financial reporting term define rule af securities exchange act abbvie internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle unite states internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation report management assess effectiveness abbvie internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal controlintegrate framework framework base assessment management conclude abbvie maintain effective internal control financial reporting december base coso criterion effectiveness abbvie internal control financial reporting december audit ernst young llp independent register public accounting firm state attestation report express unqualified opinion effectiveness abbvie internal control financial reporting december report independent register public accounting firm report abbvie independent register public accounting firm relate assessment effectiveness internal control financial reporting include form kreport independent register public accounting firm stockholder board directors abbvie inc opinion internal control financial reporting audit abbvie inc subsidiary internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission framework coso criterion opinion abbvie inc subsidiary company maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states pcaob consolidated balance sheet abbvie inc subsidiary december relate consolidated statement earning comprehensive income equity cash flow year period end december relate note report date february express unqualified opinion thereon basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management annual report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ernst young llp chicago illinois february item b information item c disclosure foreign jurisdiction prevent inspection applicable form kpart iii item director executive officer corporate governance incorporate reference information concern director nominee board director committeescommittee board director communicate board director deadline notice stockholder action consider annual meeting stockholder include abbvie inc proxy statement definitive proxy statement file march incorporate reference text find caption information executive officer abbvie code business conduct require business activity conduct compliance applicable law regulation ethical principle value director officer employee abbvie require read understand abide requirement code business conduct applicable abbvie code business conduct available corporate governance section abbvie investor relation website wwwabbvieinvestorcom waiver code business conduct director executive officer abbvie audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller person perform similar function website business day follow date amendment waiver addition abbvie disclose waiver code business conduct executive officer director website abbvie chief ethic compliance officer report executive vice president general counsel secretary public policy committee chief ethic compliance officer responsible overseeing administer monitor abbvie compliance program item executive compensation material include abbvie inc proxy statement heading director compensation executive compensation compensation committee report incorporate reference definitive proxy statement file march item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information follow table present information december abbvie equity compensation plan abbvie common stock authorize issuance number c security number security remaining issue b available exercise weight future issuance equity outstanding average exercise price compensation plan exclude option outstanding option security warrant warrant reflect plan category right right column equity compensation plan approve security holder equity compensation plan approve security holder total include share issuable abbvie incentive stock program pursuant award grant abbott adjust abbvie award connection abbvie separation abbott weightedaverage exercise price include outstanding restricted stock unit restrict stock award performance share exercise price exclude share issuable exercise stock option pursuant right grant stemcentrx equity incentive plan assume abbvie consummation acquisition stemcentrx inc december option remain outstanding plan option weightedaverage exercise price award grant plan b information concern security ownership incorporate reference material head security ownershipsecuritie ownership executive officer directors abbvie inc proxy statement definitive proxy statement file march item certain relationship relate transaction director independence material include abbvie inc proxy statement heading board director committee corporate governance material procedure approval related person transaction incorporate reference definitive proxy statement file march item principal accounting fee service material include abbvie inc proxy statement heading audit fee nonaudit fee policy audit committee pre approval audit permissible nonaudit services independent register public accounting firm incorporate reference definitive proxy statement file march form kpart iv item